• Home
  • About
  • Contact Us
  • Wishlist
Doron Scientific
  • Menu
  • Customer Support 054-5544004
    Contact Details 054-5544004 7 Hakfar st., Kiryat Ono 5552504, Israel info@doronscientific.com

  • Home
  • Suppliers
    • Life Science Products
    • Biochemical Reagents
  • Our Products
  • Promotions
  • Quote Me
Share
Doron Scientific > Products > Our Products > Antibody drug analogue

Antibody drug analogue

Add to Quote

Add to Wishlist
Compare
Category: Our Products
  • Description
  • Reviews (0)

Description

For quote and information, please contact with us via email: info@doronscientific.com

 

Product name Description Alternative names INN (International Nonproprietary Name) Target & species Storage Product Size Species Concentration Receptor identification Price quote contact
Alemtuzumab Alemtuzumab is a humanized monoclonal antibody against CD52,an antigen found on the surface of normal and malignant lymphocytes. Campath-1H,LDP-03 Alemtuzumab CD52[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ruplizumab Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.Ruplizumab is an anti-CD40L monoclonal antibody.The binding of CD40 to its ligand,CD40L is a critical element in T cell activation.In systemic lupus erythematosus,CD40L is over-expressed on T cells, B cells and monocytes. BG-9588,hu5c8 Ruplizumab CD40LG[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Apolizumab Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.Apolizumab is a humanized monoclonal antibody directed against 1D10,a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells.Apolizumab induces complement-mediated cytotoxicity,antibody-dependent cell-mediated cytotoxicity,and apoptosis of 1D10 antigen-positive B cells in vitro. Hu1D10 Apolizumab HLA-DRB[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Bevacizumab Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab, a humanized monoclonal antibody,specifically binds to all VEGF-A isoforms with high affinity. 12-IgG1,F(ab)-12 IgG1,Fab-12 IgG1,rhuMAb-VEGF Bevacizumab VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Daclizumab Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences.The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.On 22 April 2008,Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized,for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2.Regardless of the withdrawal of Zenapax, Biogen and Abbvie’s Zinbryta (daclizumab),as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis,was approved for use by the FDA in 2016. BIIB019,DAC HYP Daclizumab IL2RA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Eculizumab Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. 5G1.1,h5G1.1HuG2/G4 Eculizumab C5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-G4-kappa info@doronscientific.com
Efalizumab Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a.Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. hu1124 Efalizumab ITGAL/CD11a[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Matuzumab Matuzumab is a humanized monoclonal antibody used in cancer treatment.It has a high affinity for EGFR, frequently associated with the growth of blood vessels in malignancy,facilitating tumor growth and survival. EMD-72000,H425,h425 Matuzumab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Epratuzumab Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody,LL2 (EPB-2).This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders,such as lupus. 90Y-DOTA-hLL2,90Y-epratuzumab tetraxetan,AMG-412,90Y-hLL2,hLL2 Epratuzumab CD22[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Fontolizumab Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn’s disease. HuZAF, Fontolizumab IFNG[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Gemtuzumab Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative,a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp.calichensis.Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label.The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).By binding to the CD33 antigen on tumors,the cytotoxic agent blocks the growth of cancerous cells and causes cell death. CDP-771,CMA-676 (ADC),WAY-CMA-676,gemtuzumab ozogamicin,hP67.6 (naked),hP67.6-calicheamicin (ADC) Gemtuzumab CD33[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Cantuzumab Mertansine SB408075,huC242-DM1 Cantuzumab Mertansine CA242[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Lintuzumab Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia). 225Ac-lintuzumab,HuM195,SGN-33,SMART M195 Lintuzumab CD33[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Lorvotuzumab Mertansine Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC,Leukemia, Ovarian Cancer,Multiple Myeloma,and Merkel Cell Carcinoma,among others. BB-10901,IMGN901,huN901-DM1 Lorvotuzumab Mertansine NCAM1/CD56[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Labetuzumab Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy. hMN14 Labetuzumab CEACAM5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG-nd info@doronscientific.com
Amatuximab Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer,Ovarian Neoplasms,Pancreatic Cancer,and Mesothelioma,Malignant,among others. MORAb-009 Amatuximab MSLN[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Naptumomab Estafenatox Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma. ABR-217620,ANYARA,TTS CD3 Naptumomab Estafenatox TPBG[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab-G1-kappa info@doronscientific.com
Siplizumab Siplizumab has been shown to cause depletion of T-cells.It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits,such as certain autoimmune diseases and T-cell cancers.In addition, preclinical studies have also suggested that siplizumab,by binding to the CD2 receptor,may selectively produce cell death and reduce cancerous cells. MEDI-507 Siplizumab CD2/LFA-2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Motavizumab Motavizumab is a second generation,ultra-potent, affinity-matured,humanized mAb derived from palivizumab that reduces replication of Respiratory Syncytial Virus (RSV),a pathogen which causes lower respiratory tract disease. MEDI-524 Motavizumab RSV[Respiratory syncytial virus] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Natalizumab Natalizumab is a recombinant, humanized monoclonal antibody,binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1).Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn’s disease.Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. AN 100226,BG00002 Natalizumab ITGA4/CD49d[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Nimotuzumab Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Theraloc,hR3 Nimotuzumab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Omalizumab Omalizumab is a recombinant,humanized,monoclonal antibody against human immunoglobulin E (IgE). IGE25,olizumab,pSVIE26,rhuMab-E25 Omalizumab IGHE[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Cedelizumab ORTHOCLONE OKT4 A Cedelizumab CD4[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Palivizumab Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology,directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).Synagis is a composite of human (95%) and murine (5%) antibody sequences.The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2).The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0).Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each),contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF). MEDI-493 Palivizumab RSV[Respiratory syncytial virus] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Pertuzumab Pertuzumab (anti-HER2),a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors,impairs the ability of HER2 to bind to other members of the HER family. OMNITARG,rhuMAB 2C4 Pertuzumab ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Pexelizumab Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug.It is being investigated by Alexion Pharmaceuticals. 5G1.1-SC Pexelizumab C5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml scFv-nd-nd info@doronscientific.com
Sevirumab EV2 7,MSL 109,SDZ MSL 109 Sevirumab HCMV[Human herpesvirus 6] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Ranibizumab Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A. Fab-12 variant Y0317,RhuFab Ranibizumab VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Felvizumab SB 209763 Felvizumab RSV[Respiratory syncytial virus] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Mepolizumab Mepolizumab is a humanized IL-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.It has a molecular weight of approximately 149 kDa.It was approved by the FDA in November,2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline).Mepolizumab has been investigated in the treatment of severe nasal polyposis,among numerous other conditions.Mepolizumab is an interleukin-5 antagonist (IgG1 kappa).IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation,and survival of eosinophils.Mepolizumab binds to IL-5 with a dissociation constant of 100 pM,inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface.Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells,eosinophils, neutrophils,macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation.Mepolizumab,by inhibiting IL-5 signaling, reduces the production and survival of eosinophils;however,the mechanism of mepolizumab action in asthma has not been definitively established. SB-240563 Mepolizumab IL5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Pascolizumab Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Pascolizumab is a humanized anti-IL-4 monoclonal antibody that can inhibit upstream and downstream events associated with asthma, including (T(H)2) cell activation and immunoglobulin E production. SB-240683 Pascolizumab IL4[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Foravirumab CR4098 Foravirumab RV[Rabies virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Rafivirumab CR57 Rafivirumab RV[Rabies virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Visilizumab Visilizumab has been investigated for the treatment of Ulcerative Colitis. HuM291 Visilizumab CD3E[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-nd info@doronscientific.com
Blinatumomab Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).Blinatumomab is manufactured by Amgen Inc.and marketed under the brand Blincyto™.Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program,which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3 Blinatumomab CD19/CD3E[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml (scFv-kappa-heavy)-(scFv-heavy-kappa) info@doronscientific.com
Gevokizumab Gevokizumab has been used in trials studying the treatment of Acne Vulgaris,Osteoarthritis, Behcet’s Uveitis,Pyoderma Gangrenosum, and Behcet’s Disease Uveitis,among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states.It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors. XOMA 052 Gevokizumab IL1B[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Tadocizumab C4G1,YM-337 Tadocizumab ITGA2B_ITGB3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Yfc51.1Mab YFC51.1 Yfc51.1Mab ITGB2/CD18[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Yth12.5 YTH12.5 Yth12.5 CD3E[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Rivabazumab Pegol KB001-A Rivabazumab Pegol PcrV type III secretion system PcrV protein[Pseudomonas aeruginosa,Gram negative bacteria] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab’-G1-kappa info@doronscientific.com
14F7 14F7 14F7 ganglioside N-glycolyl GM3[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
4F2Mab 14G2a,4F2 4F2Mab ganglioside GD2/ SFRP1/SLC3A2[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus,Humanized 1mg/ml IgG2a-nd; IgG1-nd info@doronscientific.com
Huj591-Gsmab 177 Lu-J591,HuJ591-GS Huj591-Gsmab FOLH1/PSMA[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml info@doronscientific.com
Abagovomab ACA125,MEN-2234 Abagovomab idiotope of anti- Mus musculus monoclonal antibodyOC126[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Gavilimomab ABX-CBL Gavilimomab BSG/CD147[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgM-nd info@doronscientific.com
Arcitumomab CEA-Scan,IMMU-4 Arcitumomab CEACAM5/CD66e[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab’-G1-nd info@doronscientific.com
Capromab 7E11-C5.3 radiolabelled,Indium In1111 ProstaScint-,capromab pendetide Capromab FOLH2[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Campath-9H CYT-356-Y-90,Campath-9H Campath-9H CD4[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Edobacomab E5,XMMEN-0E5 Edobacomab Endotoxin[Gram negative bacteria] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgM-nd info@doronscientific.com
Edrecolomab 17-1A Edrecolomab EPCAM[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-kappa info@doronscientific.com
Enlimomab BI-RR-1,BIRR-1 Enlimomab ICAM1[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-nd info@doronscientific.com
Hnk20Mab HNK20 Hnk20Mab RSV glycoprotein F[Respiratory syncytial virus] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgA-nd info@doronscientific.com
Ibritumomab Tiuxetan Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen,which is found on the surface of normal and malignant B lymphocytes.Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.The Fab segment of the antibody targets the CD20 epitope on B-cells,allowing the radioactive yttrium to destroy the cell via production of beta particles. In-111 Zevalin,Y-90 Zevalin Ibritumomab Tiuxetan MS4A1[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Igovomab Indimacis 125,OC125 chelator DTPA Igovomab MUC16[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml F(ab’)2-G1-nd info@doronscientific.com
Imciromab R1D10 pentetate Imciromab Myosin/Cardiac[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab-G2a-kappa info@doronscientific.com
Immurait-Ll2Mab 131I-IMMU-LL2, ImmuRAIT-LL2 Immurait-Ll2Mab CD22[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-kappa info@doronscientific.com
Inolimomab Inolimomab is under investigation in clinical trial NCT04289103 (Evaluation of Efficacy and Safety of Leukotac (Inolimomab) in Pediatric Patients With Sr-agvhd). Inolimomab IL2RA[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Afelimomab MAK-195F Afelimomab TNFSF2/TNF-alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml F(ab’)2-G3-kappa info@doronscientific.com
T10B9.1A-31 MEDI-500,T10B9,T10B9.1A-31 T10B9.1A-31 T cell receptor[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgM-kappa info@doronscientific.com
Mitumomab Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice,was previously studied to treat small cell lung carcinoma in combination with BCG vaccination. BEC2 Mitumomab Ganglioside GD4[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2b-kappa info@doronscientific.com
Biciromab Indium (111In) biciromab,T2G1 Biciromab Fibrin II beta chain,fibrin[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab’-G1-kappa info@doronscientific.com
Muromonab-Cd3 Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens.More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain.It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis,antibody mediated cytotoxicity and complement-dependent cytotoxicity. OKT3 Muromonab-Cd3 CD3E[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-kappa info@doronscientific.com
Technetium (99Mtc) Nofetumomab Merpentan Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10.1 The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.Label Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.The mechanism of action in Tc-99m nm is ruled by the presence of nofetumomab, which can recognize the pancarcinoma antigen EpCAM and/or CD20/MS4A1,2 and merpentan,that acts as a linker for the binding of technetium. Technetium (99Mtc) Nofetumomab Merpentan IL3RA/CD123[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Odulimomab afolimomab,anti-LFA1 Odulimomab ITGAL/CD11a[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml F(ab’)2-G1-nd info@doronscientific.com
Milatuzumab Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others. CD74-DOX (ADC),MEDI-115,hLL1,hLL1-DOX (ADC) Milatuzumab CD74[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Oregovomab Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125. MAB-B43.13,oregovamab Oregovomab MUC16/CA125[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Cc49 CC49 Cc49 TAG-72[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml info@doronscientific.com
Satumomab Indium (111In) satumomab pendetide,OncoScint CR/OV,OncoScint CR103 Satumomab TAG-72[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Sulesomab Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes. IMMU-MN3,Technetium (99mTc) sulesomab,LeukoScan Sulesomab NCA-90[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab’-G1-nd info@doronscientific.com
Tecnemab 225.28S,Tecnemab-K-1,3-4D10,4D5-8 and UCHT1,BsF(ab’)2 v1,F(ab’)2 trastusumab/humanized UCHT1-v1,F(ab*)2 4D5-8/UCHT1-v1 Tecnemab CSPG4/HMW-MAA/CD3E/ERBB2[Homo sapiens],toxin[Clostridium perfringens] store at -80°C 100ug and 1mg Mus musculus,Humanized 1mg/ml F(ab’)2, Fab / Fab2 mix, IgG1-nd, F(ab’)2-G1-kappa info@doronscientific.com
Tositumomab Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues).It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).Binds to the CD20 antigen which is found on mature B lymphocytes.The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation. Tositumomab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-lambda info@doronscientific.com
Iodine (131I) Derlotuximab Biotin (131)I-chTNT-1/B,I-131 ch-TNT-1/B,131I-chTNT(Tumor Necrosis Therapy)-1/B Iodine (131I) Derlotuximab Biotin DNA/histone(H1) complex[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
cT84.66 90Y-cT84.66 cT84.66 CEACAM5/CD66e[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml info@doronscientific.com
Abciximab Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3.Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen,von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.Abciximab binds to the intact platelet GPIIb/IIIa receptor,which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation.This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa.By binding to the vitronectin receptor (also known as the αvβ3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion.Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion. c7E3 Abciximab ITGA2B_ITGB3[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml Fab-G1-kappa info@doronscientific.com
Alg-991 ALG-991 Alg-991 Urushiol[Toxicodendron] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgM-nd info@doronscientific.com
Basiliximab A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent,specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes.It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor.This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney. CHI621 Basiliximab IL2RA/CD25[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Bavituximab Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.Bavituximab Anti-Cancer is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid that is exposed only on the surface of tumor blood vessel cells or on cells infected with certain viruses. Bavituximab binding to the tumor blood vessel cells alerts the body’s immune system to attack the tumor and its blood supply. This has been shown to inhibit tumor growth and development. Because in healthy cells the phospholipids are concealed inside the cell, the bavituximab does not bind to them. This targets the bavituximab to the malignant cells and potentially minimizes unwanted side effects. Tarvacin ch3G4 Bavituximab Phosphatidylserine[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
cBR96 cBR96,huAnti-B4,humanized B1-8,humanized D1.3,humanized DX48,humanized K20,humanized-HCMV16,humanized-HCMV37, cBR96 Lewis Y[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa, info@doronscientific.com
Cetuximab Cetuximab is an epidermal growth factor receptor binding FAB.Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company.In the United States,a regimen of cetuximab costs approximately $30,790 for an eight-week course.Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers.Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha,thereby reducing their effects on cell growth and metastatic spread. Fab C225,IMC-225 Cetuximab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Clenoliximab Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator.It has investigated for the treatment of rheumatoid arthritis. CE9,4PE,IDEC-151 Clenoliximab CD4[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-lambda info@doronscientific.com
12D10-Fab 12D10 Fab,12D10-Fab 12D10-Fab F7[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml Fab-nd-nd info@doronscientific.com
Galiximab Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. IDEC-114 Galiximab CD80 (B7-1,CD28LG2)[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-lambda info@doronscientific.com
ICM3 IC14, ICM3 ICM3 CD14 /ICAM3[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml info@doronscientific.com
Infliximab Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn’s disease and rheumatoid arthritis.Infliximab is a IgG1κ monoclonal antibody that binds to soluble and transmembrane forms of TNF-α with high affinity to disrupt the pro-inflammatory cascade signalling.Binding of the antibody to TNF-α prevents TNF-α from interacting with its receptors.Infliximab does not neutralize TNF-β (lymphotoxin-α),a related cytokine that utilizes the same receptors as TNF-α Label.Blocked actions of TNF-α further leads to downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1, IL-6),reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes),increased levels of nuclear factor-κB inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins 3. Its inhibitory actions on TNF-α was demonstrated in human fibroblasts,endothelial cells, neutrophils, B and Tlymphocytes and epithelial cells Label.Infliximab also atteunates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes. According to a transgenic mice study that developed polyarthritis due to consitutive levels of human TNF-α,infliximab decreased synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal Label. TA-650,cA2 Infliximab TNF-alpha[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Keliximab IDEC CE9.1/SB-210396 Keliximab CD4[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-lambda info@doronscientific.com
Lumiliximab Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody,for the potential treatment of allergic conditions.Lumiliximab was developed by IDEC Pharmaceuticals,which was acquired by Biogen.Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23,a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells.CD23, also known as Fc epsilon RII,or FcεRII,is the “low affinity” receptor for IgE, an antibody isotype involved in allergy and resistance to parasites and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells,activated macrophages, eosinophils, follicular dendritic cells and platelets. IDEC-152,P5E8 Lumiliximab FCER2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Oncolym Iodine 131-ILym-1,Lym-1,Oncolym Oncolym HLA-DR10[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-nd info@doronscientific.com
Priliximab cm-MT412 Priliximab CD4[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Rituximab Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin’s Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label. IDEC-C2B8 Rituximab MS4A1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Briakinumab Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.Briakinumab targets and neutralizes interleukin-12 and interleukin-23. ABT-874 Briakinumab IL12B[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
ABX-IL8 ABX-IL8 ABX-IL8 IL8[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-nd info@doronscientific.com
Adecatumumab Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.Adecatumumab (MT201) is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has been shown to promote the proliferation, migration and invasiveness of breast cancer cells. Moreover, expression of EpCAM is associated with decreased survival in a number of cancer indications, including breast, gall bladder, bile duct, ovarian and ampullary pancreatic cancer. EpCAM has recently been shown to be expressed on cancer stem cells from breast, prostate, colon and pancreatic cancer. Clinical studies have shown a favorable safety profile and that clinical activity depends on the EpCAM target expression. MT201 Adecatumumab EPCAM[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
Adalimumab Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor 2, 3. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA 1. This drug is frequently known as Humira. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses 1. A new biosimilar to adalimumab, named adalimumab-adaz, was approved by the FDA on October 31, 2018. This biosimilar is known as Hyrimoz, and is a trademark of Novartis AG 9. D2E7 Adalimumab TNFSF2/TNF-alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Mk-4721 AGS-PSCA,MK-4721 Mk-4721 PSCA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Al-901 AL-901 Al-901 IGHE[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml info@doronscientific.com
Ganitumab Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others. AMG 479 Ganitumab IGF1R/CD221[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tuvirumab anti-hepatitis B Tuvirumab HBV[Hepatitis B virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Bertilimumab CAT-213,iCo-008 Bertilimumab CCL11[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Tralokinumab Tralokinumab is under investigation for the treatment of Alopecia Areata. Tralokinumab has been investigated for the treatment of Asthma. CAT-354 Tralokinumab IL13[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-lambda info@doronscientific.com
Ustekinumab Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.2 It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.2 It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways.Interleukin (IL)-12 and IL-23 are heterodimeric cytokines that evoke immune and inflammatory responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.The role of IL-12 and IL-23 were implicated in a variety of chronic inflammatory conditions, such as psoriasis and inflammatory bowel diseases. They modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets,2 as CD4+ T cells can differentiate into T-helper (Th) effector lineages based on the environment. Th cells can further activate the downstream pro-inflammatory mediators and transcription factors such as TNFα and IFNγ that drive innate and adaptive immunity. CNTO 1275,TT-20 Ustekinumab IL12B[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Efungumab HSP90mab,Mycograb Efungumab HSP91 homolog[Candida albicans] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml scFv-heavy-kappa info@doronscientific.com
Fresolimumab Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis. GC-1008 Fresolimumab TGFB/TGF beta[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Golimumab Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFα. Inhibition of TNFα prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed. CNTO 148 Golimumab TNFA/TNF alpha[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Lucatumumab HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies. CHIR-12,12,HCD122 Lucatumumab CD40[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Humax-Il15 AMG 714,HuMax-IL15 Humax-Il15 IL15[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
IMC-1C11 IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.IMC-1C11 is a chimerized antibody that targets the KDR receptor (also referred to as VEGFr) on vascular endothelial cells by inhibiting binding of the essential ligand, vascular endothelial growth factor (VEGF), to its receptor. KDR is a key receptor associated with tumor angiogenesis. As solid tumors cannot grow efficiently without new blood supply, use of IMC-1C11 results in the inhibition of tumor growth and death of tumor cells by apoptosis. IMC-1C11 IMC-1C11 VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml info@doronscientific.com
Ipilimumab Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells.3 CTLA-4 and CD28 are both presented on the surface of T-cells.3 Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors. BMS-734016,MDX-010,MDX-CTLA-4 Ipilimumab CTLA4/CD152[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
J695 J695,LDP-01,MLNM2201 J695 IL12A/CD18[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens,Humanized 1mg/ml IgG-nd info@doronscientific.com
Lerdelimumab CAT-152,Trabio Lerdelimumab TGFB2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-nd info@doronscientific.com
Lexatumumab Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).Lexatumumab agonizes the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), triggering the extrinsic apoptotic pathway. HGS-ETR2 Lexatumumab TNFRSF10B/CD262[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Mapatumumab HGS-ETR1,TRM-1 Mapatumumab TNFRSF10A/CD261[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
HuCC49 H22, MDX-33,H52, Huh52,HCC49,HuCC49 HuCC49 FCGR1/ITGB2/TAG-72[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Metelimumab CAT-192 Metelimumab TGFB1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
MOR101 MOR101 MOR101 ICAM1/CD54[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml Fab-nd-nd info@doronscientific.com
MOR102 MOR102 MOR102 ICAM1/CD54[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml Fab-G4-nd info@doronscientific.com
Otilimab Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA). MOR-04357,3196165,GSK3196165,MOR103 Otilimab CSF2/GM-CSF[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
MOR202 MOR202 MOR202 CD38[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
MORAb-028 MORAb-028, MaE11 MORAb-028 Ganglioside GD2/IGHE[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens,Humanized 1mg/ml IgM-nd;IgG1-nd info@doronscientific.com
Stamulumab MYO-029 Stamulumab MSTN/GDF-8[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
Nebacumab HA-1A,centoxin,septomonab Nebacumab Endotoxin[Gram negative bacteria] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgM-kappa info@doronscientific.com
Ofatumumab Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. HuMax-CD20 Ofatumumab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
OST 577 OST 577 OST 577 HBV[Hepatitis B virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml info@doronscientific.com
Panitumumab Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes. ABX-EGF,E7.6.3 Panitumumab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Regavirumab C23,MCA C23,TI-23 Regavirumab HCMV[Human herpesvirus 6] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Moxetumomab Pasudotox CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt’s lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the Pseudomonas exotoxin A (PE38) which does not have the cell-binding portion. CAT-8015,GCR-8015,HA22,moxetumomab pasudotox -tdfk Moxetumomab Pasudotox CD22[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fv-disulfide stabilized info@doronscientific.com
Votumumab Technetium (99mTc) votumumab Votumumab carcinoma associated antigen CTAA16[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG3-kappa info@doronscientific.com
Zalutumumab Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. HuMax-EGFr Zalutumumab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Zanolimumab HuMax-CD4 Zanolimumab CD4[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
CMB-401 CMB-401,hCTMO1-calicheamicin;CDP 671 CMB-401 MUC1/CD227[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
CDP571 B3 (dsFv) -PE38,LMB-9 BAY 103356,BAY W 3356,CDP571 CDP571 TNFSF2/TNF alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg 1mg/ml IgG4-kappa info@doronscientific.com
Dorlimomab Aritox 4197X-RA,MDX-RA (ricin A chain) immunotoxin Dorlimomab Aritox (ricin A chain) immunotoxin store at -80°C 100ug and 1mg Mus musculus 1mg/ml F(ab’)2-nd-nd info@doronscientific.com
Catumaxomab Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites 3. Its market authorization was withdrawn in the EU in June 2017 at the manufacturer’s request due to the company’s insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition Label. It is currently available under the brand name Removab. Musmus G2a kappa,anti-EPCAM (Ho-3/TP-A-01)/Rat sp.G2b lambda,anti-CD3E (26/II/6-1.2),TPBs01 Catumaxomab CD3E/EpCAM[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus,Rattus sp,Hybrid 1mg/ml IgG2a-kappa/G2b-lambda info@doronscientific.com
Ertumaxomab Musmus G2a kappa,anti-ERBB2 (250A/TP-A-02)/Rat sp.G2b lambda,anti-CD3E (26/II/6-1.2),TPBs03 Ertumaxomab CD3E/ERBB2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus,Rattus sp,Hybrid 1mg/ml IgG2a-kappa/G2b-lambda info@doronscientific.com
Gantenerumab Gantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial. R1450 Gantenerumab APP /Abeta42/Abeta40[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Conatumumab Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others. AMG 655,TRAIL-R2mAb,XG1-048 v w Conatumumab TNFRSF10B/CD262[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Racotumomab Racotumomab has been used in trials studying the treatment of Glioma, Wilm’s Tumor, Neuroblastoma, Retinoblastoma, and Ewing’s Sarcoma. Racotumomab Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Tenatumomab ST2146 Tenatumomab TNC/HXB[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2b-nd info@doronscientific.com
Ocrelizumab Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS. 2H7 Ocrelizumab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Camidanlumab ADCT-301(unconjugated),HuMax-TAC-ADC Camidanlumab IL2RA/CD25[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Yttrium (90Y) Clivatuzumab Tetraxetan IMMU-107 Yttrium (90Y) Clivatuzumab Tetraxetan MUC1/CD227[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tanezumab Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic. PF-04383119,RN624 Tanezumab IGHE[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Anrukinzumab Anrukinzumab has been used in trials studying the diagnostic of Asthma. IMA-638 Anrukinzumab IL13[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Dacetuzumab Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. SGN-40,huS2C Dacetuzumab CD40[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Alacizumab Pegol CDP791,g165 DFM-PEG Alacizumab Pegol KDR/VEGFR2/CD309[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml di-Fab’ info@doronscientific.com
Tigatuzumab Tigatuzumab is under investigation in clinical trial NCT00991796,CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC). CS-1008,TRA-8 Tigatuzumab TNFRSF10B/CD262[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Otelixizumab Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis. ChAglyCD,TRX4 Otelixizumab CD3E[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-lambda info@doronscientific.com
Citatuzumab Bogatox VB6-845 Citatuzumab Bogatox EPCAM/CD326[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Oportuzumab Monatox VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin A. VB4-845 Oportuzumab Monatox EPCAM/CD326[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml scFv-kappa-heavy info@doronscientific.com
Obinutuzumab Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML). GA101,RG7159,RO5072759,afutuzumab Obinutuzumab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Etaracizumab Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer. MEDI-522,hLM60 Etaracizumab ITGAV_ITGB3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Ibalizumab Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies 8,5. Hu5A8,TMB-355,TNX-355 Ibalizumab CD4 D3 domain[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Certolizumab Pegol Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).1 It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. CDP870,PHA-738144 Certolizumab Pegol TNFSF2/TNF-alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab’-G1-kappa info@doronscientific.com
Panobacumab Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa). Aerumab 11,KBPA101 Panobacumab Serotype IATS O12[Pseudomonas aeruginosa, Gram negative bacteria] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgM-kappa info@doronscientific.com
Canakinumab Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. ACZ885 Canakinumab IL1B[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tremelimumab Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. CP-675,CP-675,206,CP-675206 clone 11.2.1 Tremelimumab CTLA4/CD152[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Denosumab Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010. AMG162 Denosumab TNFSF11/CD254[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Iratumumab Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas. MDX-060 Iratumumab TNFRSF8/CD30[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Sontuzumab AS1402,huHMFG-1 Sontuzumab MUC1/CD227[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Bapineuzumab Bapineuzumab has been investigated for the treatment of Alzheimer’s Disease. AAB-001 Bapineuzumab APP Abeta[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Pagibaximab BSYX-A110,PMAB Pagibaximab Staphylococcus epidermidis lipoteichoic acid[Staphylococcus epidermidis] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Tucotuzumab Celmoleukin Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment). EMD 273066,KSA-Interleukin-2,huKS-IL2,huKS1/4-IL-2 Tucotuzumab Celmoleukin EPCAM/CD326[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Yttrium (90Y) Tacatuzumab Tetraxetan hAFP-31 Yttrium (90Y) Tacatuzumab Tetraxetan AFP[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Volociximab Volociximab ITGA5/CD49e[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-nd info@doronscientific.com
Besilesomab Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis Label. Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the Netherlands, and the United Kingdom 3. BW250/183 Besilesomab CEACAM8/CD66b[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Inotuzumab Ozogamicin Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of fully remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5. CMC-544 Inotuzumab Ozogamicin CD22[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Raxibacumab Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012. Raxibacumab Anthrax protective antigen [Bacillus anthracis] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Tefibazumab Aurexis Tefibazumab Fibrin-binding surface epitope clumping factor A[Staphylococcus aureus] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Exbivirumab 19.79.5,HepeX-B-(combination of exbivirumab and libivirumab) Exbivirumab HBV/HBsAg[Hepatitis B virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Libivirumab 17.1.41,HepeX-B-(combination of exbivirumab and libivirumab) Libivirumab HBV/HBsAg[Hepatitis B virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Urtoxazumab HuVTm1.1,TMA-15 Urtoxazumab Stx-2/SLT-II[Escherichia coli] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Belimumab Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain. LymphoStat-B,hBlySmAb-1.1 Belimumab TNFSF13B/CD257[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Elsilimomab B-E8 Elsilimomab IL6[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Epitumomab Cituxetan Epitumomab Cituxetan MUC1/CD227 [Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Pritumumab CLN G11 Pritumumab VIM [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
Talizumab C21/AL-90,HU-901,Hu901,TNX-901 Talizumab CD3E/GPRC5D[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa-lambda info@doronscientific.com
Aselizumab HuDreg-55 Aselizumab SELL/CD62L [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-nd info@doronscientific.com
Ecromeximab Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma. KM871,KW-2871 Ecromeximab ganglioside GD4[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Teneliximab chi220 Teneliximab CD40/TNFRSF5[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-nd info@doronscientific.com
Vapaliximab 2D10 Vapaliximab AOC3/VAP-1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG2-kappa info@doronscientific.com
Reslizumab Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively. CDP-835,JES1-39D10,SCH55700 Reslizumab IL5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-nd info@doronscientific.com
Erlizumab rhuMAb Erlizumab ITGB2/CD18 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Lemalesomab 78NCA-90, IMMU-MN3 Lemalesomab NCA-90 [Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Taplitumomab Paptox Taplitumomab Paptox DPEP3 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Bivatuzumab Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. BIWA4 Bivatuzumab CD44 /CD44V[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Sibrotuzumab Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer. BIBH1 Sibrotuzumab FAP[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Technetium (99Mtc) Pintumomab 170 Technetium (99Mtc) Pintumomab DPEP3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Anatumomab Mafenatox ABR-214936,pMB125 Anatumomab Mafenatox TAG-72[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab-G1-kappa info@doronscientific.com
Cixutumumab Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
IMC-A12,LY3012217 Cixutumumab IGF1R/CD221[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Elotuzumab Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. BMS-901608,PDL063;HuLuc63 Elotuzumab SLAMF7/CD319[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Farletuzumab Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. M3,MORAb-003 Farletuzumab FOLR1 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Figitumumab Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others. CP-751871 Figitumumab IGF1R/CD221[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Necitumumab Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). 11F8,IMC-11F8,LY3012211 Necitumumab EGFR/ERBB1 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Ramucirumab Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. 1121B,IMC-1121B,LY3009806 Ramucirumab KDR/CD309[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Robatumumab Robatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing’s, and Peripheral Neuroectodermal Tumor. 19D12,SCH 717454 Robatumumab IGF1R/CD221 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Siltuximab Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. CLLB8,CNTO 328 Siltuximab IL6[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Solanezumab Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial. LY2062430 Solanezumab APP Abeta,soluble monomer[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Vedolizumab Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn’s disease. LDP-02,LDP02,MLN-02,MLN0002,MLN02 Vedolizumab ITGA4_ITGB7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Daratumumab Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. HuMax-CD38 Daratumumab CD38[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Rilotumumab Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others. Rilotumumab HGF[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Epitumomab B1R1 Epitumomab MS4A1[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2a-nd info@doronscientific.com
Rovelizumab Hu23F2G Rovelizumab ITGAL/CD11a/ITGB2/CD18[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-nd info@doronscientific.com
Faralimomab 64G12 Faralimomab IFNA1[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Bectumomab Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it’s used to treat non-Hodgkin’s lymphoma. It has a radioisotope, technetium (99m TC) which it’s added. 99mTc-IMMU-LL2 Bectumomab CD22[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab’-G2a-kappa info@doronscientific.com
Nerelimomab BAYX1351 Nerelimomab TNFSF2/TNF-alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Atorolimumab P3x22914G4 Atorolimumab RHD/CD240D[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG3-kappa info@doronscientific.com
Minretumomab Mab CC-49 Minretumomab TAG-72[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Vepalimomab 1B2 Vepalimomab AOC3/VAP1[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgM-nd info@doronscientific.com
Morolimumab Morolimumab RHD/CD240D[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
Altumomab ZCE025 Altumomab CEACAM5/CD66e[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Detumomab SPECIFID(panel of 15 anti-idiotype antibodies) Detumomab B-cell lymphomas [Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1 info@doronscientific.com
Zolimomab Aritox H65-ricin A chain immunotoxin,H65-RTA Zolimomab Aritox CD5[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-nd info@doronscientific.com
Nacolomab Tafenatox r-c242Fab-SEA Nacolomab Tafenatox MUC1 sialylated CA242[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab-G1-kappa info@doronscientific.com
Enlimomab Pegol Enlimomab Pegol ICAM1/CD54[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab’-G2a-nd info@doronscientific.com
Maslimomab Maslimomab T cell receptor[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2b-nd info@doronscientific.com
Telimomab Aritox T101-ricin A chain immunotoxin,T101-RTA Telimomab Aritox CD5 [Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab-nd-nd info@doronscientific.com
Intetumumab Intetumumab has been used in trials studying the treatment of Melanoma. CNTO 095 Intetumumab ITGAV_ITGB3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Sifalimumab Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients. MDX-1103,MEDI-545 Sifalimumab IFNA1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Fezakinumab Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis. ILV-094 Fezakinumab IL22[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Brentuximab Vedotin Brentuximab vedotin是靶向CD30的新型抗体偶联药物(ADC),MMAE(一种微管抑制剂)通过共价键与抗体相连。非临床数据表明,Brentuximab vedotin的抗肿瘤活性是通过ADC与CD30表达细胞形成的复合物内化及蛋白水解切割,释放MMAE。随后MMAE与微管蛋白结合,破坏细胞内的微管网络,诱导细胞周期停滞和细胞凋亡。 SGN-35,cAC10-Val-Cit-MMAE Brentuximab Vedotin TNFRSF8/CD30 [Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Lebrikizumab Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease. MILR1444A,PRO301444 Lebrikizumab IL13[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Secukinumab Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis. AIN457 Secukinumab IL17A[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Rontalizumab Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus. RhuMAB IFNalpha Rontalizumab IFNA1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Girentuximab Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC). WX-G250,cG250 Girentuximab CA9[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Iodine (124I) Girentuximab Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT). 124I_WX-G250,124I_cG250 Iodine (124I) Girentuximab CA9[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Suvizumab KD-247 Suvizumab HIV-1[Human immunodeficiency virus 1] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Glembatumumab CDX-011 (DOX),CR011,glembatumumab vedotin (ADC) Glembatumumab GPNMB extracellular domain[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Dalotuzumab Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer. MK-0646 Dalotuzumab IGF1R/CD221[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Benralizumab Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly fully depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma. BIW-8405,KHK4563,MEDI-563 Benralizumab IL5RA/CD12[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Mavrilimumab Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis. CAM-3001 Mavrilimumab CSF2RA/CD116 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-lambda2 info@doronscientific.com
Teprotumumab Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor.8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received “breakthrough therapy” designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED.7 Thyroid eye disease is a potentially debilitating complication of Graves’ Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries – teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease. RO4858696-000 Teprotumumab IGF1R/CD221[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
Drozitumab PRO95780,anti-DR5,rhuMAb DR5 Drozitumab TNFRSF10B/TRAILR2/CD262[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Ensituximab Ensituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer. NOE-102,NPC-1C Ensituximab MUC5AC[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Foralumab NI-0401 Foralumab CD3E[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Itolizumab T1h Itolizumab CD6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Olaratumab Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. 3G3,IMC-3G3,LY3012207 Olaratumab PDGFRA/PDGFR2/CD140a[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Olokizumab Olokizumab has been used in trials studying the treatment of Crohn’s Disease. CDP 6038 Olokizumab IL6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Oxelumab R4930,RG4930,RO4989991,huMAb OX40L Oxelumab TNFSF4/CD252[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Roledumab LFB-R593 Roledumab RHD[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Samalizumab Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia. ALXN6000,Anti-CD200,hB7V3V2 G2G4 Samalizumab CD200[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-G4-kappa info@doronscientific.com
Trastuzumab Emtansine Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech’s trastuzumab antibody linked to ImmunoGen’s cell-killing agent, DM1. T-DM1 combines two strategies– anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)–to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. PRO132365,RG3502,T-DM1,trastuzumab-MCC-DM1 Trastuzumab Emtansine ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Atinumab 6A3-IgG4,ATI355 Atinumab RTN4/NOGO[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Carlumab Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer. CNTO 888 Carlumab CCL2/MCP-1/MCAF/SCYA2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Enavatuzumab PDL 192 Enavatuzumab TNFRSF12A/CD266[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Enokizumab A humanized immunoglobulin G1k anti-interleukin-9 mAb. 7F3com-2H2,MEDI-528 Enokizumab IL9[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Etrolizumab Etrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis. Anti-Beta7,PRO145223,RG7413,rhuMAb Beta7 Etrolizumab ITGA4_ITGB7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Fulranumab Fulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others. 4D4,AMG-403,JNJ-42160443 Fulranumab NGF/NGFB[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Icrucumab Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer). 18F1,IMC-18F1,LY3012212 Icrucumab FLT1/ VEGFR-1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Mogamulizumab Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8.On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy 7.Mogamulizumab is derived from Kyowa Hakko Kirin’s POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2. AMG-761,KW-0761 Mogamulizumab CCR4/CD194[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Namilumab Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis. MT203 Namilumab CSF2/GM-CSF[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Onartuzumab Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others. MetMAb,OA-5D5,PRO 143966 Onartuzumab MET/RCCP2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa -[Fc-G1] info@doronscientific.com
Ponezumab Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer’s Disease). PF-04360365,RN-1219,clone 9TL Ponezumab APP Abeta40[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Radretumab L19-131 I,L19-SIP Radretumab FN EDB[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml [(scFv-heavy-kappa)-IGHE-CH4]2 info@doronscientific.com
Tregalizumab Tregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis. BT-061, hB-F5, hBF5(H37L_L4M) Tregalizumab CD4[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ublituximab Ublituximab has been used in trials studying the treatment of B-cell Lymphoma, Neuromyelitis Optica, Mantle Cell Lymphoma, Non-Hodgkins Lymphoma, and Marginal Zone Lymphoma, among others. LFB-R603, TG-1101,TGTX-1101 Ublituximab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Urelumab Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer – Solid Tumors and B-Cell Non-Hodgkin’s Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex’s UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. BMS-663513 Urelumab TNFRSF9/CD137 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Vesencumab Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors). MNRP1685A Vesencumab NRP1/VEGF165R extracellular domain[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Blosozumab Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal. LY2541546 Blosozumab SOST(sclerostin)[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Brodalumab Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. AMG827,KHK4827 Brodalumab IL17RA/CD217[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Crenezumab Crenezumab has been used in trials studying the treatment of Alzheimer’s Disease. MABT5102A,RG7412 Crenezumab APP Abeta42 and Abeta40[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Ficlatuzumab Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid Leukemia, among others. AV-299,SCH 900105 Ficlatuzumab HGF[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ixekizumab Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. LY2439821 Ixekizumab IL17A [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Narnatumab Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors). IMC RON-8,RON8 Narnatumab MST1R/CD136[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Ozoralizumab Ozoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis. ATN-103 Ozoralizumab ALB/TNFSF2/TNF-alpha/TNFA [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml VH-VH’-VH info@doronscientific.com
Pateclizumab Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis). MLTA3698A,PRO283698,RG7416 Pateclizumab LTA/TNFSF1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Sirukumab Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid. CNTO 136 Sirukumab IL6 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tabalumab Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others. LY2127399 Tabalumab TNFSF13B/CD257[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Vatelizumab Vatelizumab has been used in trials studying the treatment of Ulcerative Colitis. GBR500 Vatelizumab ITGA2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Cantuzumab Ravtansine IMGN242,huC242-DM4 Cantuzumab Ravtansine MUC1 CA242[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Indatuximab Ravtansine BT-062,nBT062-DM4 Indatuximab Ravtansine SDC1/CD138[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-kappa info@doronscientific.com
Sarilumab Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6 1. Sarilumab was developped by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate 4. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient 3. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms 2. REGN88,SAR153191 Sarilumab IL6R/CD126[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Caplacizumab Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression. ALX-0081,PMP12A2h1-linker AAA-PMP12A2h1,caplacizumab-yhdp Caplacizumab VWF  A1 domain[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml VH-VH info@doronscientific.com
Inclacumab Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular. LC1004-002,RO4905417 Inclacumab SELP[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Flanvotumab 20D7S,IMC-20D7S Flanvotumab TYRP1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Romosozumab Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7,8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9,2019. 785A070802,AMG 785,CDP-7851,romosozumab-aqqg,sclerostin Ab Romosozumab SOST[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Solitomab MT110 Solitomab CD3E/EpCAM[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml (scFv-kappa-heavy)-(scFv-heavy-kappa) info@doronscientific.com
Quilizumab Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis). 47H4,Anti-M1 prime,MEMP1972A,RG-7449 Quilizumab IGHE[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Patritumab Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others. AMG888,U3-1287 Patritumab ERBB3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Actoxumab CDA 1,MBL-CDA1,MDX-066,MK-3415A (combination of actoxumab and bezlotoxumab) Actoxumab toxin A[Clostridium difficile] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Bezlotoxumab Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Used to reduce the recurrence of Clostridium difficle infection in adults receiving antibiotic therapy to treat C. difficile infection and high risk of recurrence. MK-6072,CDB-1,MDX-1388,MK-3415A (combination of actoxumab and bezlotoxumab),formerly CDB 1 Bezlotoxumab toxin B[Clostridium difficile] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Alirocumab Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood. REGN727,SAR-236553, Alirocumab PCSK9[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Clazakizumab Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis. ALD-518,BMS-945429 Clazakizumab IL6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Demcizumab Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. OMP-21M18 Demcizumab DLL4 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Duligotuzumab Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant. MEHD7945A,RG-7597, Duligotuzumab ERBB3 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Enoticumab REGN-421,SAR153192 Enoticumab DLL4 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Fasinumab Fasinumab has been used in trials studying the basic science and treatment of Sciatica, Back Pain, Low Back Pain, Osteoarthritis, Hip, and Abdominal Pain Upper, among others. REGN475,SAR164877 Fasinumab NGF/NGFB [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Futuximab Futuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors). DS 992,Sym 004 (combination of modotuximab and futuximab) Futuximab EGFR  domain III /ERBB1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Imgatuzumab Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer). GA201,RG7160,RO5083945 Imgatuzumab EGFR [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Lampalizumab Lampalizumab has been used in trials studying the treatment of Geographic Atrophy. AFD, Anti-fD,Anti-FACTOR D,FCFD4514S,RG7417 Lampalizumab CFD[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Ligelizumab Ligelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma and Atopic Dermatitis, among others. CL-2C Ligelizumab IGHE[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Lirilumab Lirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others. BMS-986015,IPH2102 Lirilumab KIRD2 subgroup[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Nivolumab Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer. BMS-936558,MDX-1106,ONO-4538 Nivolumab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Ocaratuzumab AME-133v,LY2469298 Ocaratuzumab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Orticumab BI-204,MLDL-1278A,R-7418 Orticumab oxLDL[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Parsatuzumab Parsatuzumab is under investigation in clinical trial NCT01366131,Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE). RG7414,RO5490248 Parsatuzumab EGFL7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Perakizumab RG4934,RO5310074 Perakizumab IL17A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Placulumab Placulumab has been used in trials studying the treatment of Rheumatoid Arthritis. ART621,CEP-37247,PN0621 Placulumab TNFSF2/TNF-alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml [V-kappa]2-Fc info@doronscientific.com
Simtuzumab Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis. AB0024,GS-6624 Simtuzumab LOXL2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Vorsetuzumab SGN-70,h1F6 Vorsetuzumab CD70/TNFSF7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Vorsetuzumab Mafodotin SGN-75 Vorsetuzumab Mafodotin CD70/TNFSF7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Modotuximab Modotuximab is under investigation in clinical trial NCT03549338 (Sym004 Versus Futuximab or Modotuximab in Patients With mCRC). DS 1024,Sym 004 (combination of modotuximab and futuximab) Modotuximab EGFR/ERBB1 domain III[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Concizumab Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder. Anti-TFPI,NN7415,mab2021 Concizumab TFPI[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Evolocumab Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9). AMG 145,Anti-PCSK9 Evolocumab PCSK9[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Dupilumab Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis. CD124,REGN668,SAR231893 Dupilumab IL4R/CD124[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Tildrakizumab Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3.The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter 7.
A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5.
MK-3222, SCH900222 Tildrakizumab IL23A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Dusigitumab Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer. MEDI-573 Dusigitumab IGF1/IGF2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-nd info@doronscientific.com
Nesvacumab Nesvacumab is under investigation in clinical trial NCT01997164,Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME). REGN-910 Nesvacumab ANGPT2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-nd info@doronscientific.com
Pidilizumab Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma). CT-011 Pidilizumab PDCD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ozanezumab Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. GSK-1223249 Ozanezumab RTN4/NOGO[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-nd info@doronscientific.com
Seribantumab Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others. MM-121,SAR256212 Seribantumab ERBB3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Bimagrumab Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others. BYM338 Bimagrumab ACVR2A/ACVR2B[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Pinatuzumab Vedotin Pinatuzumab vedotin is under investigation in clinical trial NCT01691898,A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL). ACD22-VCMMAE,DCDT2980S,FCU2803,RG-7593,RO5541072-000 Pinatuzumab Vedotin CD22[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Polatuzumab Vedotin Polatuzumab vedotin is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E.Label This medication was granted accelerated FDA approval on 10 June 2019.5. ACD79B-VCMMAE,DCDS4501A,FCU2711,RO5541077-000,polatuzumab vedotin-piiq Polatuzumab Vedotin CD79B[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Pritoxaximab Shigamabs-(drug name for the combination of pritoxaximab and setoxaximab),caStx1 Pritoxaximab shiga toxin type 1 B subunit[Escherichia coli] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Setoxaximab Shigamabs-(drug name for the combination of pritoxaximab and setoxaximab),caStx2 Setoxaximab Stx2/SLT-II[Escherichia coli] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Lodelcizumab LGT209,NVP-LGT209 Lodelcizumab PCSK9[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Idarucizumab Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc).Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, fully and sustained reversal of the anticoagulant effects of dabigatran.Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199. aDabi-Fab,anti-dabigatran,antidote for dabigatran Idarucizumab dabigatran etexilate mesylate[Drug] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Eldelumab MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. BMS-936557,MDX-1100 Eldelumab CXCL10[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Dinutuximab Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the fully eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. 14.18,MAb-14.18,MOAB Ch14.18 Dinutuximab ganglioside GD2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Tosatoxumab KBSA301 Tosatoxumab alpha toxin[Staphylococcus aureus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Codrituzumab Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma). GC33,RG7686,RO5137382 Codrituzumab GPC3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tarextumab Tarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer. OMP-59R5 Tarextumab CD52[Homo sapiens] store at -80°C 100ug and 1mg Caninized 1mg/ml IgG2-kappa-lambda info@doronscientific.com
Guselkumab Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation 2. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis.Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. CNTO-1959 Guselkumab IL23A[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Tovetumab Tovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies. MEDI-575 Tovetumab PDGFRA / PDGFR2/ CD140a[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Vantictumab Vantictumab has been used in trials studying the treatment of Solid Tumors, Pancreatic Cancer, and Stage IV Pancreatic Cancer. OMP-18R5 Vantictumab FZD[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Anetumab Ravtansine Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer). BAY 94-9343,unconjugated:BAY 86-1903 Anetumab Ravtansine MSLN[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Pembrolizumab Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. MK-3475 Pembrolizumab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Margetuximab  Margetuximab is under investigation in clinical trial NCT03133988 (Margetuximab Expanded Access Program). MGAH-22 Margetuximab ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Anifrolumab Anifrolumab has been investigated for the treatment of Scleroderma. MDX-1333,MEDI-546 Anifrolumab IFNAR1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Enfortumab Vedotin Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link.It is similar to brentuximab vedotin, another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4.The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name PadcevTM. AGS-22CE,AGS-22M,AGS-22M6E,unconjugated:AGS-22C3 or AGSM6 Enfortumab Vedotin PVRL4[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Lifastuzumab Vedotin Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer). DNIB0600A (conjugate),MNIB2126A (non conjugate) Lifastuzumab Vedotin SLC34A2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Aducanumab Aducanumab has been used in trials studying the treatment of Alzheimer’s Disease. BART,BIIB-037 Aducanumab APP  Abeta[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Fletikumab Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis). 15D2,NN-8226,NNC-0109-0012 Fletikumab IL20 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Dapirolizumab Pegol CDP7657 Dapirolizumab Pegol CD40LG/CD154[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab’-G1-kappa info@doronscientific.com
Sofituzumab Vedotin DMUC5754A (conjugate),MMUC1206A (nonconjugate) Sofituzumab Vedotin MUC16/CA125[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ulocuplumab BMS-936564, MDX-1338 Ulocuplumab CXCR4/CD184[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Ralpancizumab PF-05335810,RN317 Ralpancizumab PCSK9/NARC1/ PC9[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Bococizumab Bococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. PF-04950615,RN-316 Bococizumab PCSK9/NARC1/ PC9[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Bimekizumab Bimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis. CDP4940 Bimekizumab IL17A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Otlertuzumab TRU-016 Otlertuzumab CD37/TSPAN26[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml VH-V-kappa-CH2-CH3 info@doronscientific.com
Abituzumab Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic. DI-17E6,EMD 525797 Abituzumab ITGAV /CD51[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Coltuximab Ravtansine Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL). SAR3419 Coltuximab Ravtansine CD19 [Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Ontuxizumab Ontuxizumab (MORAb-004) is monoclonal antibody that interferes with endosialin (tumor endothelial marker-1). MORAb-004 Ontuxizumab CD248[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Brontictuzumab OMP-52M51 Brontictuzumab NOTCH1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-lambda info@doronscientific.com
Denintuzumab Mafodotin SGN-19A,SGN-CD19A,hBU12-491,unconjugated:huBU12 Denintuzumab Mafodotin CD19[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Diridavumab CR-6261,CR6261 Diridavumab influenza A virus hemagglutinin HA2 subunit from various strains[Influenza A virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Abrilumab Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181). AMG 181,MEDI-7183 Abrilumab ITGA4_ITGB7[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Emibetuzumab Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. LA480,LY-2875358 Emibetuzumab MET/RCCP2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Varlilumab Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett’s Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others. 1F5,CDX-1127 Varlilumab CD27/TNFRSF7[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Pasotuxizumab BAY 2010112,BITE MT112,MT-112 Pasotuxizumab CD3E/FOLH1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml (scFv-heavy-kappa)-(scFv-heavy-lambda) info@doronscientific.com
Lulizumab Pegol Lulizumab pegol is under investigation in clinical trial NCT02843659,Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren’s Syndrome. BMS-931699 Lulizumab Pegol CD28 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml V-kappa info@doronscientific.com
Vanucizumab Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors. RG-7221,RG7221,RO5520985 Vanucizumab ANGPT2/VEGFA[Homo sapiens], store at -80°C 100ug and 1mg Humanized 1mg/ml VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa info@doronscientific.com
Emactuzumab Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors). RG7155,RO5509554 Emactuzumab CSF1R/CD115[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Lumretuzumab Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer. RG-7116,RO5479599 Lumretuzumab ERBB3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Begelomab BT 5/9,SAND-26 Begelomab DPP4/TP103/CD26[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG2b-kappa info@doronscientific.com
Imalumab BAX069,BAX69 Imalumab MIF[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Lenzilumab KB-003 Lenzilumab CSF2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Firivumab CT-P22 Firivumab Influenza A virus hemagglutinin HA[Influenza A virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Avelumab Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. MSB-0010718C,MSB0010682 Avelumab CD274/B7-H1/PDL1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Remtolumab A-1230717,ABT-122 Remtolumab IL17A/TNFSF2/TNF-alpha/TNFA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml [VH-VH’-H-Gamma1-VL-VL’-C-kappa]-dimer info@doronscientific.com
Obexelimab Obexelimab (XmAb5871) is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function. Obexelimab is the first drug candidate to our knowledge that targets FcγRIIb inhibition. XmAb5871 Obexelimab CD19[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Lacutamab IPH4102 Lacutamab KIR3DL2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tafasitamab MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19 Tafasitamab CD19[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-G2-kappa info@doronscientific.com
Vobarilizumab (20A11-9mer-ALB11),ALX-0061 Vobarilizumab ALB/IL6R/CD126 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml VH-VH’ info@doronscientific.com
Atezolizumab Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research. MPDL3280A,RG7446 Atezolizumab CD274/B7-H1/PDL1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Lokivetmab CAN34D3-65,PF-06443537 Lokivetmab IL31[Canis lupus familiaris] store at -80°C 100ug and 1mg Caninized 1mg/ml IgG2-kappa info@doronscientific.com
Durvalumab Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it fullyly blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.(适用于人源及非人源化小鼠) MEDI4736 Durvalumab CD274/B7-H1/PDL1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Evinacumab REGN 1500 Evinacumab ANGPTL3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Vandortuzumab Vedotin DSTP-3086S,DSTP3086S,MSTP2109A,RG-7450,RG7450 Vandortuzumab Vedotin STEAP1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Indusatumab Vedotin Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others. 5F9vcMMAE,MLN-0264,unconjugated:MLN2045 or 5F9 Indusatumab Vedotin GUCY2C[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Andecaliximab GS-5745 Andecaliximab MMP9[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-kappa info@doronscientific.com
Elgemtumab LJM716,NVS201010 Elgemtumab ERBB3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tesidolumab Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others. LFG 316, LFG-316, LFG316 Tesidolumab C5[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Brolucizumab Brolucizumab, also known as RTH258 or ESBA1008,4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration.Brolucizumab was granted FDA approval in October 2019.6. ESBA-1008,ESBA1008,RTH258 Brolucizumab VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml scFv-kappa-heavy info@doronscientific.com
Dectrekumab QAX-576 Dectrekumab IL13[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Nemolizumab CIM 331 Nemolizumab IL31RA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Isatuximab Isatuximab is IgG1 chimeric monoclonal antibody that targets specific epitopes on the CD38 receptor of plasma cells and can trigger a variety of unique mechanisms of action, including the promotion of programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is expressed at high levels on MM cells and is a cell surface receptor target for antibody therapy in MM and other malignant tumors. SAR-650984,hu38SB19 Isatuximab CD38[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Lilotomab HH1 Lilotomab CD37[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Lutetium (177Lu) Lilotomab Satetraxetan 177lu-DOTA-HH1 Lutetium (177Lu) Lilotomab Satetraxetan CD37/TSPAN26[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Indusatumab 5F9,MLN2045 Indusatumab GUCY2C[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Bermekimab Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis). MABp1,Xilonix Bermekimab IL1A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Istiratumab Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer). MM-005,MM-141 Istiratumab ERBB3/IGF1R/CD221[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa -[scFv]2 info@doronscientific.com
Pepinemab VX-15,VX15/2503 Pepinemab SEMA4D[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Obiltoxaximab ETI-204 Obiltoxaximab Anthrax protective antigen[Bacillus anthracis] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Navivumab CT-P23 Navivumab Influenza A virus hemagglutinin HA[Influenza A virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Vadastuximab Talirine Vadastuximab talirine (SGN-CD33A) is a novel antibody-conjugated drug targeting CD33, which is composed of pyrrole diazoxide dimeric compounds; CD33 is expressed in most patients with acute myeloid leukemia (AML). SGN-CD33A,h2H12ec-SGD-1910, h2H12ec-mc-val-ala-SGD-1882 Vadastuximab Talirine CD33[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Inebilizumab MEDI-551 Inebilizumab CD19[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Pamrevlumab FG-3019 Pamrevlumab CTGF/IGFBP-8[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Cergutuzumab Amunaleukin CEA-IL-2v,RG7813,RO-6895882 Cergutuzumab Amunaleukin CEACAM5/CEA/CD66e[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IG-Gamma1 -[IL2 (interleukin 2, IL-2) 21-153, engineered]1_kappa info@doronscientific.com
Trevogrumab Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men). REGN-1033, REGN1033, SAR-391786 Trevogrumab MSTN/GDF8[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Opicinumab Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants). BIIB-033 Opicinumab LINGO1/LRRN6A/LERN1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Labetuzumab Govitecan Labetuzumab govitecan (IMMU-130) is an antibody drug conjugate that integrates anti-CEACAM5 antibody labetuzumab with cytotoxic drugs (http://www.chemdrug.com/) SN-38. Carcinoembryonic antigens corresponding to antibodies can be detected in plasma (http://www.chemdrug.com/sell/76/) and have high expression in many solid tumors (especially CRC). IMMU-130,hMN-14-SN-38,hMN-14-SN-38 ADC,hMN14-CL-SN-38 Labetuzumab Govitecan CEACAM5/CEA/CD66e[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Sacituzumab Govitecan IMMU-132,hRS7-SN-38,hRS7-SN-38-ADC,hRS7-[CL-SN-38] Sacituzumab Govitecan TACSTD2/M1S1/ EGP-1/TROP2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Clivatuzumab Tetraxetan hPAM4,hPAM4 IgG-DOTA,hPAM4-DOTA Clivatuzumab Tetraxetan MUC1/CD227[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ascrinvacumab Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma. PF-03446962 Ascrinvacumab ACVRL1/SKR3/TGF-B/ TSR-I[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Monalizumab IPH-2201,NN-8765,NNC-0141-0000-0100,NNC-141-01000,anti-NKG2A,humZ270 Monalizumab KLRC1/NKG2A/CD159a/CD94[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Bleselumab Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients). 4D11,ASKP-1240 Bleselumab CD40/ TNFRSF5[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Emicizumab ACE-910,RG6013,hBS910 Emicizumab F10/F9  activated form[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Plozalizumab Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. MLN-1202,anti-CCR2,hu1D9 Plozalizumab CCR2/CD192[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Risankizumab Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie. BI 655066,risankizumab-rzaa Risankizumab IL23A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Dinutuximab Beta Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the fully eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. APN311,CH14.18/CHO,ch14.18 Dinutuximab Beta ganglioside GD2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Rovalpituzumab Tesirine SC0001-SCX,SC0002 Rovalpituzumab Tesirine DLL3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Rovalpituzumab Rovalpituzumab DLL3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tisotumab Vedotin HuMax-TF-ADC, TF-011-MMAE Tisotumab Vedotin F3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Ifabotuzumab KB-004 Ifabotuzumab EPHA3/REK4[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tezepelumab Tezepelumab is under investigation in clinical trial NCT03406078 (Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma). AMG 157,AMG-157,MEDI-9929,MEDI9929,anti-TSLP-Receptor (TSLP-R; Crl2) Tezepelumab TSLP[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Rinucumab REGN-2176,REGN-2176-3 (combination of aflibercept and ricunumab),REGN2176 Rinucumab PDGFRB/ PDGFR-1/CD140b[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Mirvetuximab Soravtansine IMGN853,M9346A-sulfo-SPDB-DM4 Mirvetuximab Soravtansine FOLR1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Afasevikumab MCAF-5352A,NI-1401,RG-7624,RO5553110 Afasevikumab IL17A /IL17F[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tisotumab HuMax-TF Tisotumab F3 /CD142[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Landogrozumab Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer. LY-2495655 Landogrozumab MSTN/GDF8[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Tilavonemab ABBV-8E12, C2N-8E12 Tilavonemab MAPT[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-kappa info@doronscientific.com
Gontivimab ALX-0171,VR-465 Gontivimab RSV glycoprotein F[Respiratory syncytial virus] store at -80°C 100ug and 1mg Lama glama 1mg/ml VH-VH-VH info@doronscientific.com
Bevacizumab Beta ABP 215 Bevacizumab Beta VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Olendalizumab ALXN1007 Olendalizumab C5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-G4-kappa info@doronscientific.com
Satralizumab SA-237 Satralizumab IL6R[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Cabiralizumab FPA-008 Cabiralizumab CSF1R/CD115[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Xentuzumab BI 836845 Xentuzumab IGF1/IGF2 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Daclizumab Beta Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab Beta IL2RA/CD25[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Enoblituzumab MG-A271 Enoblituzumab CD276/B7-H3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Refanezumab Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients). GSK-249320 Refanezumab MAG/SIGLEC-4A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Mirvetuximab M9346A Mirvetuximab FOLR1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Blontuvetmab AT-004,VT-007 Blontuvetmab MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Caninized 1mg/ml IgG2-kappa-lambda info@doronscientific.com
Tamtuvetmab AT-005,AT005 Tamtuvetmab NGF/NGFB[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-nd info@doronscientific.com
Crotedumab Crotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2. REGN-1193 Crotedumab GCGR[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Rivabazumab BA1126 Rivabazumab PcrV[Pseudomonas aeruginosa,Gram negative bacteria] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab’-G1-kappa info@doronscientific.com
Navicixizumab Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors). OMP-305B83 Navicixizumab DLL4/VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Prezalumab AMG 557,MEDI-5872 Prezalumab ICOSLG/B7-H2/B7RP-1/CD275[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Laprituximab Emtansine IMGN-289,J2898A-SMCC-DM1 Laprituximab Emtansine EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Laprituximab J2898A Laprituximab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Naratuximab Emtansine IMGN-529,K7153A-SMCC-DM1 Naratuximab Emtansine CD37/TSPAN26[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Naratuximab K7153A Naratuximab CD37/TSPAN26[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Vadastuximab h2H12ec Vadastuximab CD33/SIGLEC3[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Carotuximab TRC-105,c-SN6j Carotuximab ENG[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Timolumab 8c10,BTT-1023,BTT1023,SI-3106,SI-636,r8c10 Timolumab AOC3/VAP1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Lanadelumab Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the reported clinical trials.Lanadelumab was developed by Shire and FDA approved on August 28, 2018.5. X124-G01,DX-2930 Lanadelumab KLKB1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Vonlerolizumab MOXR-0916,MOXR0916,RG-7888,RO7021608 Vonlerolizumab TNFRSF4/CD134[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Galcanezumab LY2951742/galcanezumab is a fully humanized monoclonal antibody against human calcitonin gene-related peptide (CGRP) that is developed by ELi Lilly and Company.This therapy is given as a single subcutaneous injection twice a month and ongoing clinical trials for the agent are for episodic and chronic migraine as well as cluster headaches. LY-2951742,galcanezumab-gnlm Galcanezumab CALCA/CGRP1/CALCB/CGRP2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Domagrozumab PF-06252616 Domagrozumab MSTN /GDF8[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Erenumab Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine . AMG 334,erenumab-aooe Erenumab CALCRL/CGRP-R[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Birtamimab 2A4,ELT1-01,NEOD-001 Birtamimab SAA1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Suptavumab H1H3592P3,REGN 2222,SAR-438584,SAR438584 Suptavumab RSV glycoprotein F[Respiratory syncytial virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Setrusumab Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density). BPS-804,MOR-05813 Setrusumab SOST[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Iodine (131I) Apamistamab Iomab-B Iodine (131I) Apamistamab PTPRC/CD45[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Duvortuxizumab JNJ-64052781,MGD011,RES192M1.2 Duvortuxizumab CD19/CD3E[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml scFv -h-CH2-CH3(_scFv)_h-CH2-CH3 info@doronscientific.com
Rozanolixizumab Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy). UCB-7665 Rozanolixizumab FCGRT[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Lupartumab BAY 1112623 Lupartumab LYPD3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Depatuxizumab Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors. ABT-806 Depatuxizumab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Depatuxizumab Mafodotin Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme. ABT-414,unconjugate:ABT-806 Depatuxizumab Mafodotin EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Fremanezumab LBR-101,PF-04427429,RI-307,RN-307,TEV-48125,fremanezumab-vfrm Fremanezumab CALCA /CALCB[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Burosumab KRN-23,UX-023 Burosumab FGF23[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Eptinezumab Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals.7 Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).8,1,2,3 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults. ALD-403 Eptinezumab CALCA /CALCB[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Gemtuzumab Ozogamicin Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. CDP-771,CMA-676,WAY-CMA-676 Gemtuzumab Ozogamicin CD33[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Elezanumab ABT-555,AE12-1Y-QL(derived from parental mAb AE12-1 and AE12-1Y) Elezanumab RGMA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Lutikizumab ABT-981 Lutikizumab IL1A /IL1B[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml [VH-VH’-H-Gamma1-VL-VL’-C-kappa]-dimer info@doronscientific.com
Dezamizumab GSK-2398852 Dezamizumab APCS[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Telisotuzumab Vedotin ABBV-399,ABT-700-vcMMAE Telisotuzumab Vedotin MET/RCCP2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Telisotuzumab ABT-700,hz224G11 Telisotuzumab MET/RCCP2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Aprutumab BAY 1179470 Aprutumab FGFR2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Aprutumab Ixadotin BAY 1187982 Aprutumab Ixadotin FGFR2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Utomilumab Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer). PF-05082566, PF-2566 Utomilumab TNFRSF9/CD137[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Vunakizumab SHR-1314 Vunakizumab IL17A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Camrelizumab Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy). SHR-1210 Camrelizumab PDCD1/PD-1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Rosmantuzumab OMP-131R10 Rosmantuzumab RSPO3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Sacituzumab hRS7 Sacituzumab TACSTD2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ranevetmab NV-01 Ranevetmab NGF/NGFB[Mus musculus] store at -80°C 100ug and 1mg Caninized 1mg/ml IgG1-kappa info@doronscientific.com
Brazikumab AMG-139,MEDI2070 Brazikumab IL23A[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-lambda info@doronscientific.com
Lupartumab Amadotin BAY 1129980 Lupartumab Amadotin LYPD3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Emapalumab Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.1,5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.5 As well, emapalumab was given the status of PRIME by the EMA. NI-0501,emapalumab-lzsg Emapalumab IFNG [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Crizanlizumab SelG1 Crizanlizumab SELP[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Trastuzumab Duocarmazine SYD985,trastuzumab vc-seco-DUBA (trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole) Trastuzumab Duocarmazine ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ravulizumab Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris®. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a “next-generation” eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label. ALXN-1210,ravulizumab-cwvz Ravulizumab C5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG2-G4-kappa info@doronscientific.com
Tomaralimab Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function). OPN-305 Tomaralimab TLR2/CD282[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-kappa info@doronscientific.com
Maftivimab REGN3470-3471-3479 Maftivimab Zaire Ebola virus[Zaire ebolavirus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Garetosmab REGN2477 Garetosmab INHBA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Flotetuzumab MGD-006,MGD006,RES234,S80880 Flotetuzumab CD3E/IL3RA/CD123[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus;Humanized 1mg/ml VH-VL-VH’-VL’ info@doronscientific.com
Losatuxizumab Vedotin ABBV-221 Losatuxizumab Vedotin EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Losatuxizumab ABT-806,PR-1316749 Losatuxizumab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Varisacumab AT-001,GNR-011,r84 Varisacumab VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Letolizumab BMS-986004 Letolizumab CD40LG/CD154[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml (VH-CH2-CH3)2 info@doronscientific.com
Suvratoxumab Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893). MEDI4893 Suvratoxumab alpha toxin[Staphylococcus aureus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Frunevetmab NV-02 Frunevetmab NGF/NGFB[Mus musculus] store at -80°C 100ug and 1mg Felinized 1mg/ml IgG1-kappa info@doronscientific.com
Lesofavumab MHAB5553A,RG70026,RO7045557 Lesofavumab Influenza B virus hemagglutinin[Influenza B virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Gedivumab Gedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers). MHAA4549A,RO6876802;RG7745 Gedivumab Influenza A virus hemagglutinin HA[Influenza A virus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Azintuxizumab ABBV-383,PR-1471272 Azintuxizumab SLAMF7/CRACC/CD319[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Azintuxizumab Vedotin ABBV-838 Azintuxizumab Vedotin SLAMF7/CRACC/CD319[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Trastuzumab Deruxtecan Trastuzumab deruxtecan is HER2-targeted antibody-coupled drug (ADC) for patients with HER2-positive metastatic breast cancer who have previously received two or more anti-HER2 treatments. DS-8201,DS-8201a Trastuzumab Deruxtecan ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Selicrelumab CP-870,893,RG-7876,RO-7009789 Selicrelumab CD40/TNFRSF5[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Lacnotuzumab MCS-110 Lacnotuzumab CSF1/MCSF[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Gilvetmab AH-PD1 Gilvetmab PDCD1/PD1/CD279[Canis lupus familiaris] store at -80°C 100ug and 1mg Caninized 1mg/ml IgG2-kappa info@doronscientific.com
Cosfroviximab c13C6-FR1-N Cosfroviximab Zaire Ebola virus [Zaire ebolavirus] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Porgaviximab c2G4-N Porgaviximab Zaire Ebola virus[Zaire ebolavirus] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Larcaviximab c4G7-N Larcaviximab Zaire Ebola virus[Zaire ebolavirus] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Oleclumab MEDI-9447 Oleclumab NT5E/CD37[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Zanidatamab ZW-25,ZW25 Zanidatamab ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa/scFv-h-CH2-CH3 info@doronscientific.com
Tomuzotuximab CetuxiMab-GEX,GEXMab52201 Tomuzotuximab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Timigutuzumab GEXMab73,GT-MAb7.3-GEX,TrastuzuMab-GEX Timigutuzumab ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Gatipotuzumab PankoMab,PankoMab-GEX,hPankoMab Gatipotuzumab MUC1/CD227[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Loncastuximab Tesirine ADCT-402,RB4v1.2-SG-3249 Loncastuximab Tesirine CD19[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Zolbetuximab Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer). GC-182,IMAB-362,IMAB362,claudiximab Zolbetuximab CLDN18[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Talacotuzumab Talacotuzumab, also known as JNJ-56022473 (and formerly CSL-362) is a humanized IgG1 monoclonal antibody designed to bind to and neutralize CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. CSL-362-AML,CSL362,JNJ-56022473 Talacotuzumab NOTCH2/ NOTCH3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Sirtratumab AGS15C,Ha15-10ac12,Ha15-10ac12.1 Sirtratumab SLITRK6[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Gimsilumab Gimsilumab is a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF). MORAb-022 Gimsilumab CSF2 /GM-CSF[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tislelizumab Tislelizumab (BeiGene) is a humanized monoclonal antibody that was designed to bind to the PD-1 receptor and prevent binding of PD-L1. In addition, tislelizumab was designed to minimize binding to Fc-gamma-receptors (FcyR) on macrophages. Preclinical studies found that binding to FcyR on macrophages compromises the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. BGB-A317 Tislelizumab PDCD1/PD1/ CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Ianalumab Ianalumab (VAY736) is monoclonal antibody that depletes B cells and blocks B cell activation factor receptors. VAY-736 Ianalumab TNFRSF13C/CD268[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Loncastuximab RB4v1.2 Loncastuximab CD19 [Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Mosunetuzumab Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3ε), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. BTCT4465A,RG-7828,RO7030816 Mosunetuzumab CD3E/MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Spartalizumab Spartalizumab (PDR001) is humanized IgG4 monoclonal antibody that targets binding to PD-1 with sub-nanomolar affinity to block its interaction with PD-L1 / PD-L2, thereby preventing PD-1 mediated inhibitory signals Transduction leads to T cell activation. NPVPDR001,NVS240118,PDR001 Spartalizumab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Ladiratuzumab hLIV22 Ladiratuzumab SLC39A6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Atidortoxumab ASN-1,ASN-100 (combination of atidortoxumab and berlimatoxumab) Atidortoxumab alpha toxin[Staphylococcus aureus];bi-component leukocidins [Staphylococcus aureus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Berlimatoxumab ASN-100 (combination of atidortoxumab and berlimatoxumab),ASN-2 Berlimatoxumab LukGH[Staphylococcus aureus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tiragolumab Tiragolumab is fully humanized monoclonal antibody. Tiragolumab targets TIGIT and directly or indirectly activates anti-tumor immune responses by acting on the activation pathways of APC and T cells and NK cells to achieve the purpose of eliminating tumor cells. MTIG-7192-A,MTIG-7192A,MTIG7192A,RG-6058,RO-7092284,RO7092284 Tiragolumab TIGIT/VSIG9/VSTM3[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Iladatuzumab MCDS0593A,RO7032005 Iladatuzumab CD79B[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Mirikizumab Mirikizumab is humanized IgG4 monoclonal antibody that targets p19 subunit binding to IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn’s disease (CD), of which the treatment of moderate to severe plaque psoriasis is already in phase III clinical practice. LY-3074828 Mirikizumab IL23A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Cofetuzumab PF-06523435,hu24 Cofetuzumab PTK7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Prasinezumab Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets α-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson’s disease pathology.Prasinezumab targets α-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with α-synuclein misfolding and/or its transmission. PRX002,RG-7935 Prasinezumab SNCA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Bemarituzumab Bemarituzumab is subtype-selective humanized monoclonal antibody against FGFR2b. The FIGHT study aims to evaluate the efficacy of its combination chemotherapy in untreated advanced gastric cancer or gastroesophageal junction cancer. FPA-144,FPA114-A Bemarituzumab FGFR2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Zenocutuzumab Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer). MCLA-128,PB4188,R040517 Zenocutuzumab ERBB2/ERBB3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Sirtratumab Vedotin AGS-15E,AGS-15vcMMAE,AGS15C SGD-1006,ASG-15ME,Ha15-10ac.1vcMMAE Sirtratumab Vedotin SLITRK6[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Ladiratuzumab Vedotin Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) that we are developing for the treatment of breast cancer. Most metastatic breast cancers express LIV-1, which also has been detected in a number of other cancers, including melanoma, prostate, ovarian, uterine, and cervical cancers. Ladiratuzumab vedotin consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC agent is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response. SGN-LIV1A Ladiratuzumab Vedotin SLC39A6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Iladatuzumab Vedotin DCDS0780A,RO7032005 Iladatuzumab Vedotin CD79B[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Camidanlumab Tesirine Camidanlumab tesirine (ADCT-301) is an antibody-drug conjugate (ADC) combining Genmab’s HuMax®-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. Camidanlumab tesirine targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, except for regulatory T cells (Tregs), which are known to be immunosuppressive. Camidanlumab tesirine is in development under an agreement between Genmab and ADC Therapeutics, under which Genmab owns 25% of the product rights. ADCT-301,HuMax-TAC-ADC Camidanlumab Tesirine IL2RA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Tibulizumab Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. LY 3090106,LY-3090106,LY3090106 Tibulizumab IL17A/TNFSF13B/CD257[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa-[scFv]2 info@doronscientific.com
Cofetuzumab Pelidotin Anti-PTK7 ADC,PF-06647020,PTK7-ADC Cofetuzumab Pelidotin PTK7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Narsoplimab Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP-2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity. OMS721 Narsoplimab MASP2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-lambda info@doronscientific.com
Relatlimab Relatlimab targets LAG-3. LAG-3 only helps to increase the activity of T cells against tumors, but also inhibits other T cells. BMS-986016,ONO-4482 Relatlimab LAG3/CD223[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Crovalimab Crovalimab,a Sequential Monoclonal Antibody Recycling Technology (SMART) antibody was engineered for extended self-administered subcutaneous dosing of small volumes in diseases amenable for C5 inhibition. RG-6107,RO7112689,SKY-59 Crovalimab C5[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Belantamab Mafodotin Belantamab mafodotin, also known as GSK2857916, is an immunoconjugate that contains humanized anti-BCMA monoclonal antibody, a linker, and the cytotoxic agent auristatin F. It specifically kills cancer cells by targeting BCMA to deliver cytotoxic agents specifically to MM cells. 2857916,GSK2857916 Belantamab Mafodotin TNFRSF17[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ontamalimab Ontamalimab (SHP 647) is fully human IgG2 monoclonal antibody against mucosal localization protein cell adhesion molecule (MADCAM1). PF-00547659,PF-547659,SHP647 Ontamalimab MADCAM1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Adalimumab Beta Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). ABP 501 Adalimumab Beta TNF/TNFSF2/TNF-alpha[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Trastuzumab Beta Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2.Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. ABP 980, ABP-980 Trastuzumab Beta ERBB2/EGFR2/CD340 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Netakimab BCD-085 (Netakimab, trade mark Efleira®) is recombinant human anti-interleukin-17 (IL-17) monoclonal antibody. IL-17 is an inflammation-related cytokine. When its function is abnormal, it will cause autoimmunity and inflammatory diseases. AG1-25 Netakimab IL17A[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens,Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Cusatuzumab Cusatuzumab is SIMPLE antibody targeting CD70, which is an immune checkpoint target involving hematological malignancies, various solid tumors, and various autoimmune diseases. cusatuzumab aims to block CD70 by killing CD70-expressing cancer cells through complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis and enhancing antibody-dependent cell-mediated cytotoxicity Immunological monitoring of solid tumors. ARGX-110 Cusatuzumab CD70/TNFSF7[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-lambda info@doronscientific.com
Faricimab Faricimab (RG7716) is bispecific antibody drug that simultaneously targets Angiopoietin-2 (Ang-2) and VEGF-A. RG7716,RO6867461 Faricimab ANGPT2/VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens;Humanized 1mg/ml IgG1-kappa-lambda info@doronscientific.com
Romilkimab SAR156597,huTBTI3_2_1 Romilkimab IL13/IL4[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml [VH-VH’-H-Gamma1-VL-VL’-C-kappa]-dimer info@doronscientific.com
Cibisatamab Cibisatamab (CEA-TCB) is T cell bispecific antibody that binds to carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has one single CD3 epsilon chain binding site and two CEA binding sites on T cells (which regulates the binding affinity to cancer cells with high expression of CEA on the cell surface). This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation is triggered by binding to CEA on the surface of cancer cells and CD3 on T cells, cytokine secretion and release of cytotoxic particles. CEA TCB,RG-7802,RO-6958688 Cibisatamab CD3E/CEACAM5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa/lambda with domain crossover info@doronscientific.com
Iscalimab Iscalimab (CFZ533) is fully human monoclonal antibody targeting differentiation cluster 40 (CD40), which cy pathway, preventing CD40 pathway signaling and CD40 + cell type activation It has become a new therapy for the treatment of solid organs and related autoimmune diseases. CFZ-533,NVP-CFZ533,OM11-62MF Iscalimab CD40/TNFRSF5[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Bersanlimab BI-505 Bersanlimab ICAM1/CD54[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Vopratelimab Vopratelimab is  IgG1 ICOS antibody. Studies shows that vopratelimab can activate both effector T cells and suppress intratumoral regulatory T cells (Treg cells) that weaken the immune response. JTX-2011 Vopratelimab ICOS/CD278[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Sutimlimab Sutimlimab is anti-C1s antibody, and studies have shown that it can significantly increase hemoglobin levels in patients with primary cold agglutinin disease. Cold agglutinin disease (CAD) is an acquired autoimmune hemolytic anemia (AIHA). In cold environments, clinical symptoms related to erythrocyte agglutination occur in cold parts of the body (for example, net Cyanosis or cyanosis of extremities) and hemolytic anemia. BIVV009,IPN-009,TNT009 Sutimlimab C1S[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Etigilimab Etigilimab is human-derived monoclonal antibody. Etigilimab targets TIGIT. It started clinical research for the treatment of advanced solid tumors in the United States in 2017 and is currently in clinical phase I. OMP-313M32 Etigilimab TIGIT/VSTM3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Abrezekimab CDP7766,UCB-4144,VR-942 Abrezekimab IL13[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Lenvervimab Lenvervimab (GC1102) is recombinant hepatitis B immunoglobulin developed by the Korean biopharmaceutical company GCPharma. It aims to reduce blood HBsAg levels to improve the sustained virological response, thereby improving the therapeutic effect. GC-1102 Lenvervimab HBV[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ravagalimab ABBV-323 Ravagalimab CD40/TNFRSF[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Leronlimab Leronlimab (PRO140) is humanized IgG4 monoclonal antibody that can target blocking chemokine receptor 5 (CCR5), which is a cellular receptor that is involved in HIV infection, tumor metastasis, and immune signal transduction Play multiple roles. HuPRO-140,PA-14,PRO-140 Leronlimab CCR5/CD195[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Imaprelimab PRX-003 Imaprelimab MCAM[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Cetrelimab Cetrelimab (JNJ-63723283) is a Programmed Cell Death Receptor-1 (PD-1) Inhibitor. JNJ-63723283 Cetrelimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Onvatilimab JNJ-61610588 Onvatilimab VSIR[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Mitazalimab Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study). ADC-1013,JNJ-64457107 Mitazalimab CD40/TNFRSF5[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-lambda info@doronscientific.com
Tepoditamab MCLA-117, PB9122 Tepoditamab CD3E/CLEC12A[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Enapotamab Enapotamab AXL[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Enapotamab Vedotin Enapotamab vedotin (HuMax®-AXL-ADC) is an antibody-drug conjugate (ADC) targeted to AXL.  AXL is a unique receptor tyrosine kinase (RTK) that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation,migration, and invasion. HuMax-AXL-ADC Enapotamab Vedotin AXL[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Samrotamab Vedotin ABBV-085,PR-1498487-MMAE Samrotamab Vedotin LRRC15[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Samrotamab PR-1498487 Samrotamab LRRC15[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Belantamab Belantamab mafodotin (GSK2857916) is antibody-conjugated drug that connects humanized anti-BCMA antibodies with cytotoxic agents, and specifically targets BCMA to deliver cytotoxic agents into MM cells to kill cancer cells effect. 2857916,GSK2857916,J6M0,J6M0-mcMMAF Belantamab TNFRSF17/CD269[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Olinvacimab Olinvacimab is currently in phase II trials for a combination therapy to treat cancer with Merck’s Keytruda. SSS-23,TTAC-0001,tanibirumab Olinvacimab KDR/VEGFR2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa-lambda info@doronscientific.com
Murlentamab Murlentamab is monoclonal antibody that binds AMHRII (cell membrane) and CD16 (macrophage surface) with high affinity. 3C23K,GM102 Murlentamab AMHR2[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Abelacimab NVS250519 Abelacimab F11[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Budigalimab ABBV-181,PR-1648817 Budigalimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Cemiplimab Cemiplimab is fully human PD-1 antibody. The first indication for marketing application is metastatic / local advanced squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway that can help the immune system fight cancer cells. REGN-2810,SAR-439684,cemiplimab-rwlc Cemiplimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Dilpacimab ABT-165,PR-1283233 Dilpacimab DLL4/VEGFA[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Dostarlimab Dostarlimab (TSR-042) is humanized anti-PD-1 monoclonal antibody jointly developed by TESARO and AnaptysBio. It binds to the PD-1 receptor with high affinity, thereby blocking its binding to PD-L1 and PD-L2 ligands. ANB-011,TSR-042 Dostarlimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Frovocimab Antibody drug targeting PCSK9 LY-3015014 Frovocimab PCSK9[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Gosuranemab Gosuranemab (BIIB092) is humanized IgG4 monoclonal anti-body that targets N-terminal tau protein (eTau). The basic principle of this treatment is based on the hypothesis that eTau is involved in the spread of pathological diseases. BMS-986168,IPN-002,huIPN-002 Gosuranemab MAPT[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-kappa info@doronscientific.com
Marstacimab Marstacimab is fully human monoclonal antibody that binds to and neutralizes TPFI activity and is under development for treatment of hemophilia. Marstacimab is a laboratory-engineered monoclonal antibody designed to treat hemophilia A and B patients, with or without inhibitors. It works by blocking and effectively preventing TFPI from performing the anticoagulant function that it naturally carries out in the human body. PF-06741086 Marstacimab TFPI[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Nirsevimab MEDI-8897 Nirsevimab RSV[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Orilanolimab SYNT-001 Orilanolimab FCGRT[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG4-kappa info@doronscientific.com
Omburtamab Omburtamab is monoclonal antibody  targeting B7-H3 antigen expressed in a variety of human solid tumors. Omburtamab (alias: 8H9, formerly known as Burtomab) is a monoclonal antibody linked to radioisotope and capable of binding to the B7-H3 antigen on the surface of neuroblastoma cells. Direct injection into cerebrospinal fluid, bypassing the blood-brain barrier, accurately targeting neuroblastoma in the central nervous system, to avoid damage to other tissues (such as learning disabilities and developmental delays often caused by conventional radiotherapy outside the brain). 8H9,Mab 8H9 Omburtamab CD276/B7-H3/B7RP-2[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Prolgolimab BCD-100 (Prolgolimab) this product is recombinant human anti-PD-1 monoclonal antibody. BCD-100 Prolgolimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens,Chimeric 1mg/ml IgG1-kappa-lambda info@doronscientific.com
Osocimab Osocimab is long-acting, fully human monoclonal antibody that inhibits factor XIa. BAY 1213790 Osocimab F11[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Rolinsatamab PR-1594804,h16f Rolinsatamab PRLR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Sintilimab Sintilimab is fully human anti-PD-1 antibody used for tumor immunotherapy. It adopts the IgG4 molecular framework and has its hinge region sequence modified (S228P). Sindilimum acts as a blocker of programmed death receptor 1 (PD-1), which can bind to PD-1 molecule on the surface of T cells and release the inhibitory effect of the PD-1 pathway on T cells. IBI-308 Sintilimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Spesolimab BI655130 (Spesolimab) is humanized monoclonal IgG1 antibody (mAb) against IL36R. BI 655130 Spesolimab IL36RN[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tabituximab ONC-005,OTSA101 Tabituximab FZD10[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Temelimab Temelimab is monoclonal antibody designed to neutralize the pathogenic envelope protein pHERV-W Env encoded by the HERV-W member of the human endogenous retrovirus family. This protein plays a key role in the development of MS, and may also be a key factor in the onset and development of type 1 diabetes. GNbAC-1, GNbAC1 Temelimab HERV and MRSV envelope protein[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Toripalimab Toripalimab is humanized monoclonal antibody targeted at programmed death receptor 1 (PD-1), used to treat patients with unresectable or metastatic melanoma who have failed previous systemic system therapy, and is intended for treatment Breast cancer, lymphoma, malignant melanoma, urogenital cancer and other types of solid tumors. Toripalimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Zampilimab UCB-7858, UCB7858 Zampilimab TGM2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Gancotamab Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician’s Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients). MM-302 Gancotamab ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml scFv-heavy-lambda info@doronscientific.com
Rolinsatamab Talirine ABBV-176,DC-1630993,h16f Rolinsatamab Talirine PRLR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Tabituximab Barzuxetan OTSA101-DTPA-90Y,OTSA101-DTPA,OTSA101-SS01 Tabituximab Barzuxetan FZD10[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Mezagitamab TAK-079 Mezagitamab CD38 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-lambda info@doronscientific.com
Cobolimab Cobolimab is antibody drug against TIM3. TSR-022 Cobolimab HAVCR2/TIM3/CD366[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Levilimab BCD-089 Levilimab IL6R[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Etokimab Etokimab,previously known as ANB020,is an antibody that inhibits the activity of IL-33,a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases. ANB020 Etokimab IL33[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Naxitamab Naxitamab is humanized monoclonal antibody that targets GD2 antigen. GD2 antigen is expressed on the surface of tumors generated by neuroectoderm, including tumors such as neuroblastoma, melanoma, and osteosarcoma. Naxitamab can trigger antibody-mediated cytotoxicity and activate the complement system in the immune system by binding to the GD2 antigen on the surface of the tumor, thereby achieving the effect of killing the tumor. Hu3F8 Naxitamab Ganglioside GD2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Vofatamab  Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma). MFGR1877S Vofatamab FGFR3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Donanemab Donanemab (LY3002813 or N3pG-Aβ monoclonal antibody) is under development in Alzheimer’s disease. LY3002813 Donanemab APP[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Teclistamab JNJ-64007957 Teclistamab MS4A1[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml Fab-G2b-kappa info@doronscientific.com
Disitamab Vedotin RC48 (disitamab vedotin) indication is HER2-positive locally advanced or metastatic urothelial carcinoma. RC48 is the first antibody-drug conjugate (ADC) to enter clinical research in China. ADC are made up of monoclonal antibodies, linkers and toxins, which can precisely attack cancer cells like precision-guided missiles. RC48 targets the HER2 protein on the surface of tumors and can accurately identify and bind to cancer cells, penetrate the cell membrane into its interior, and kill cancer cells. RC48 Disitamab Vedotin ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Pozelimab Pozelimab is research-based, fully human monoclonal antibody, invented using Regeneron’s proprietary VelocImmune technology, which aims to block the complement signaling pathway by binding to complement factor C5. It also prevents the destruction (hemolysis) of red blood cells that cause paroxysmal nocturnal hemoglobinuria and other disease symptoms. REGN-3918 Pozelimab C5[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Glenzocimab ACT-017 Glenzocimab GP6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml Fab-G1-kappa info@doronscientific.com
Serclutamab Talirine ABBV-321 Serclutamab Talirine EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Serclutamab DC-1630423,PR-1594407 Serclutamab EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tamrintamab Pamozirine DC-1728001,SC-003,SC-003 ADC Tamrintamab Pamozirine Adenocarcinoma antigen[Homo sapiens] store at -80°C 100ug and 1mg Mus musculus 1mg/ml IgG1-kappa info@doronscientific.com
Tamrintamab SC-003 mAb,SC-Mab003,SC34.28ss1 Tamrintamab CD3 epsilon /TNFRSF17[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens,Chimeric 1mg/ml IgG4-lambda info@doronscientific.com
Cetuximab Sarotalocan cetuximab-IR700 Cetuximab Sarotalocan EGFR[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa info@doronscientific.com
Elipovimab Elipovimab (formerly GS-9722;PGT121-derived broadly neutralizing antibody). GS-HIV Elipovimab HIV-1 gp120[Human immunodeficiency virus 1] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Volagidemab AMG 477,REMD-477 Volagidemab GCGR[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Cendakimab 13C5.5,ABT-308,RPC-4046 Cendakimab IL13[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Balstilimab PD-1 monoclonal antibody balstilimab is used to treat cervical cancer, balstilimab monotherapy and anti-CTLA-4 monoclonal antibody zalifrelimab combined with balstilimab for metastatic cervical cancer. AGEN2034 Balstilimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Zalifrelimab Balstilimab combined with zalifrelimab in the treatment of metastatic cervical cancer. AGEN1884 Zalifrelimab CTLA4/CD152[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Garadacimab CSL312 Garadacimab F12[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-lambda info@doronscientific.com
Magrolimab Magrolimab is anti-CD47 monoclonal antibody designed to promote phagocytosis of cancer cells by macrophages. Its purpose is to interfere with the recognition of CD47 by SIRPα receptors on macrophages, thereby blocking the self-protection signals used by cancer cells to avoid being swallowed by macrophages. Hu5F9-G4 Magrolimab CD47 [Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Ieramilimab Antibody drugs targeting LAG3, Ieramilimab of Novartis began research on the target. LAG-525 Ieramilimab LAG3 [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Plamotamab Plamotamab (XmAb13676) is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3).An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life,stability and ease of manufacture on plamotamab.CD20 is highly expressed on B-cell tumor cells, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells.Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. The structural stability and modularity enabled by the XmAb Bispecific Fc domain allowed the tuning of plamotamab’s potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation. XmAb-13676 Plamotamab CD3E/MS4A1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa / scFv-h-CH2-CH3 info@doronscientific.com
Vibecotamab XmAb14045 Vibecotamab CD3 epsilon/ IL3RA[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml IgG1-kappa / scFv-h-CH2-CH3 info@doronscientific.com
Tidutamab XmAb-18087 Tidutamab CD3 epsilon/SSTR2[Homo sapiens] store at -80°C 100ug and 1mg Chimeric, Humanized 1mg/ml IgG1-kappa / scFv-h-CH2-CH3 info@doronscientific.com
Nimacimab RYI-018 Nimacimab CNR1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Semorinemab Semorinemab is anti-Tau antibody that can help clear Tau protein deposits in the brain. RO-7105705 Semorinemab MAPT[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Bedinvetmab ZTS-00508841 Bedinvetmab NGF/NGFB[Canis lupus familiaris] store at -80°C 100ug and 1mg Caninized 1mg/ml IgG2-lambda info@doronscientific.com
Relfovetmab ZTS-00084768 Relfovetmab NGF/NGFB[Felis catus] store at -80°C 100ug and 1mg Felinized 1mg/ml IgG1-kappa info@doronscientific.com
Atoltivimab Atoltivimab can target Ebola virus and is expected to be used for post-exposure prevention of this deadly virus. REGN-3470-3471-3479 Atoltivimab Zaire Ebola virus[Zaire ebolavirus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Nidanilimab CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies. CAN-04, Nidanilimab IL1RAP[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Quetmolimab Antibody drug targeting CX3CL1. E-6011 Quetmolimab CX3CL1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG2-kappa info@doronscientific.com
Cinpanemab BIIB-054 Cinpanemab SNCA [Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-lambda info@doronscientific.com
Disitamab RC48-0 Disitamab ERBB2/EGFR2/CD340[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Envafolimab Envafolimab (KN035) is the first humanized anti-PD-L1 single domain antibody and new fusion protein of human IgG1 Fc. Compared with the PD-1/PD-L1 antibody that is currently on the market and under development, it has obvious advantages. . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and rapid tumor penetration, thereby improving the compliance of cancer patients with medication and improving the quality of life of patients. It is in line with the future trend of long-term management of cancer as a chronic disease. KN-035 Envafolimab CD274/PD-L1/B7-H1[Homo sapiens] store at -80°C 100ug and 1mg Chimeric 1mg/ml (VH-CH2-CH3)2 info@doronscientific.com
Actinium (225Ac) Lintuzumab Satetraxetan HuM195 Actinium (225Ac) Lintuzumab Satetraxetan CD33[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Amivantamab JNJ-61186372,JNJ-6372 Amivantamab EGFR/ME/RCCP2[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Anetumab Corixetan BAY 2287409 Anetumab Corixetan MSLN store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Astegolimab AMG-282,MSTT-1041A,RG-6149,RO-7187807 Astegolimab IL1RL1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Avdoralimab IPH-5401,NN-8210,NNC-0215-0384 Avdoralimab C5AR1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Avizakimab BOS161721 Avizakimab IL21[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Axatilimab SNDX-6352,UCB-6352 Axatilimab CSF1R/CD115[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Batoclimab Batoclimab (HBM9161) is fully human antibody targeting neonatal Fc receptor (FcRn). It can accelerate the degradation of autoantibodies in patients with optic neuromyelitis spectrum diseases and other autoimmune diseases. FcRn expression is upregulated by pro-inflammatory cytokines (such as TNF-α) and prolongs the half-life of IgG and serum albumin by reducing lysosomal degradation in endothelial cells and bone marrow-derived cells. Blocking the FcRn-IgG interaction can accelerate the degradation of autoantibodies and mitigate the onset of various pathogenic IgG-mediated autoimmune diseases, including myasthenia gravis, thyroid eye disease, optic neuromyelitis spectrum disease, and immunity Thrombocytopenia. HL161 Batoclimab FCGRT[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Befovacimab BAY-1093884 Befovacimab TFPI [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens;Humanized 1mg/ml IgG2-lambda info@doronscientific.com
Benufutamab GEN1029 Benufutamab TNFRSF10B/TRAILR2/ CD262[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Cosibelimab Cosibelimab is a fully-human monoclonal IgG1 antibody that blocks the interaction between PD-L1 and PD-1 and certain receptors called B7.1 by binding to PD-L1. CK-301 Cosibelimab CD274/PD-L1/B7-H1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Dovanvetmab ZTS-00521505 Dovanvetmab IL31[Felis catus] store at -80°C 100ug and 1mg Felinized 1mg/ml IgG1-kappa info@doronscientific.com
Encelimab TSR-033 Encelimab LAG3/CD223[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Epcoritamab Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology.It targets CD20 on the B-cells,a clinically well-validated target that is expressed in a wide variety of B-cell malignancies.Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies. GEN3013 Epcoritamab CD3E;MS4A1/CD20[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens;Chimeric 1mg/ml IgG4-kappa-lambda info@doronscientific.com
Fianlimab The antibody drug against LAG-3 is indicated for malignant tumors. REGN3767 Fianlimab LAG3/CD223[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Gatralimab GZ-402668 Gatralimab CD52[Homo sapiens] store at -80°C 100ug and 1mg Chimeric;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Glofitamab CD20-TCB (2:1),RG-6026 Glofitamab CD3E/MS4A1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa-lambda info@doronscientific.com
Gremubamab Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults). MEDI3902 Gremubamab PcrV[Bradyrhizobium sp.ANU 289,Gram negative bacteria] store at -80°C 100ug and 1mg Homo sapiens,Humanized 1mg/ml VH-CH1-VH-V-KAPPA-CH2-CH3 info@doronscientific.com
Ivuxolimab PF-04518600 Ivuxolimab TNFRSF4/CD134[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Lodapolimab The antibody drug against PDL1. LY3300054 Lodapolimab PDCD1/PD-1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Manelimab BCD-135 Manelimab CD274/PD-L1/B7-H1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-lambda info@doronscientific.com
Mavezelimab MK-4280 Mavezelimab LAG3/CD223[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Mirzotamab ABBV-155 Mirzotamab CD276/B7-H3[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Mirzotamab Clezutoclax ABBV-155 Mirzotamab Clezutoclax CD276/B7-H3[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Nurulimab BCD-145 Nurulimab CTLA4[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Odesivimab REGN-3470-3471-3479,REGN-3470/REGN-3471/REGN-3479 Odesivimab Zaire Ebola virus[Zaire ebolavirus] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Odronextamab The antibody drug against MS4A1, CD20-CD3 bispecific antibody REGN1979 (odronextamab) has shown good results when treating a variety of B-cell NHL patients. REGN-1979 Odronextamab CD3E[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Pacmilimab CX-072 Pacmilimab CD274/PD-L1/B7-H1[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG4-kappa info@doronscientific.com
Patritumab Deruxtecan U3-1287 Patritumab Deruxtecan ERBB3 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Petosemtamab MCLA-158 Petosemtamab EGFR/ERBB1/LGR5[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG1-kappa info@doronscientific.com
Praluzatamab CX-2009 Praluzatamab ALCAM/CD166[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Praluzatamab Ravtansine CX-2009 Praluzatamab Ravtansine ALCAM/CD166[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Retifanlimab Retifanlimab (INCMGA-0012) is anti-PD-1 monoclonal antibody. INCMGA0012 is currently in the stage of clinical proof of concept (PoC). At the same time, Incyte is exploring the efficacy of INCMGA0012 monotherapy in high-satellite unstable endometrial cancer and Merkel cell carcinoma. INCMGA-00012,MGA-012 Retifanlimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Chimeric,Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Sasanlimab Antibody drug against PD1. PF-06801591 Sasanlimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Serplulimab HLX10 Serplulimab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Sonelokimab M-1095,MSB-0010841 Sonelokimab ALB,IL17A[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml VH-VH’-VH info@doronscientific.com
Tafolecimab GPRC5D / CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is commonly known as tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of anti-CD3 antibody introduced F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were simultaneously introduced into the IgG4 constant region. IBI-306 Tafolecimab PCSK9[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml IgG2-kappa info@doronscientific.com
Tilvestamab Ab-2,BGB-149 Tilvestamab PCSK9[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tinurilimab BAY-1834942 Tinurilimab CEACAM6[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Vibostolimab MK-7684 Vibostolimab TIGIT/VSIG9/VSTM3[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Zagotenemab Zagotenemab is an antibody drug that targets TAU protein, and has started Phase II clinical trial in April 2018. LY-3303560 Zagotenemab MAPT[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG4-kappa info@doronscientific.com
Zelminemab AMG-301 Zelminemab ADCYAP1R1[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Ziltivekimab Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). COR-001 Ziltivekimab IL6 [Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens;Humanized 1mg/ml IgG1-kappa info@doronscientific.com
Tocilizumab Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody,prevents binding of IL-6 to the IL-6R,thereby inhibiting both classic and trans-signaling.Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Atlizumab,MRA/R-1569/RHPM-1/RO-4877533 Tocilizumab  IL-6R store at -80°C 100ug and 1mg 1mg/ml IgG1 info@doronscientific.com
Basilixumab Basiliximab;CHI-621/SDZ-CHI-621 Basilixumab IL-2 receptor store at -80°C 100ug and 1mg 1mg/ml IgG1k info@doronscientific.com
Tavolimab MEDI0562 Tavolimab TNF- SF4 receptor I[Homo sapiens] store at -80°C 100ug and 1mg Homo sapiens 1mg/ml TBP-1:tumor necrosis factor (TNF) binding protein variant 1 info@doronscientific.com
Veltuzumab Veltuzumab is a monoclonal antibody which,as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin’s lymphoma. hA20/IMMU-106 Veltuzumab  CD20 receptors[Homo sapiens] store at -80°C 100ug and 1mg 1mg/ml info@doronscientific.com
Teplizumab This is anti-CD3 monoclonal antibody used to prevent or delay the development of clinical type 1 diabetes (T1D) in high-risk groups. High-risk groups refer to the presence of 2 or more T1D-related autoantibodies in the body. MGA-031/MGA031;PRV-031 Teplizumab CD3 store at -80°C 100ug and 1mg 1mg/ml info@doronscientific.com
Pembrolizumab Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. MK-3475 Pembrolizumab PDCD1/PD1/CD279[Homo sapiens] store at -80°C 100ug and 1mg Humanized 1mg/ml IgG1 info@doronscientific.com

Reviews

There are no reviews yet.

Be the first to review “Antibody drug analogue” Cancel reply

Our Products

Antibody Detection Using...

Antibody Detection Using Serological Assays- AAT Bioquest
Our Products

Caprico Biotechnologies, Inc....

Caprico Biotechnologies, Inc. – antibodies

Related Products

  • Quickview

    Our Products

    SARS-CoV-2 Proteins and Inhibitor Screening Kit

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    SARS-CoV-2 Proteins and Inhibitor Screening Kit

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    PCR Detection Of Viral DNA/RNA

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    PCR Detection Of Viral DNA/RNA

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Tetrodotoxin citrate , TTX, CAS 18660-81-6

    Description: Na+ channel blocker Purity: > 98% Tetrodotoxin (TTX) is an established potent and selective blocker of some Nav channels. Moreover, TTX sensitivity is used to define subclasses of Nav channels. It is widely used both to probe Nav activity and to reduce or block excitability in neurophysiological preparations.

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Tetrodotoxin citrate , TTX, CAS 18660-81-6

    Add to Quote

    Description: Na+ channel blocker Purity: > 98% Tetrodotoxin (TTX) is an established potent and selective blocker of some Nav channels. Moreover,…

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    LC Laboratories – Signal Transduction Reagents

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    LC Laboratories – Signal Transduction Reagents

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Hycult Biotech is a ISO-13485 certified manufacturer of research reagents

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Hycult Biotech is a ISO-13485 certified manufacturer of research reagents

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Mpro from COVID-19 virus – New product

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Mpro from COVID-19 virus – New product

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Complement and Thromboinflammation in SARS-CoV-2

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Complement and Thromboinflammation in SARS-CoV-2

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Antibody Detection Using Serological Assays- AAT Bioquest

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Antibody Detection Using Serological Assays- AAT Bioquest

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Protease Substrates for COVID-19 Drug Screening

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Protease Substrates for COVID-19 Drug Screening

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Caprico Biotechnologies, Inc. – antibodies

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Caprico Biotechnologies, Inc. – antibodies

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Stem Cell, Lentivirus ,Mycoplasma Detection and RT-PCR- TransGen Biotech

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Stem Cell, Lentivirus ,Mycoplasma Detection and RT-PCR- TransGen Biotech

    Add to Quote

    • Add to Wishlist
    • Compare
  • Quickview

    Our Products

    Rapid Protein Extraction- Invent Biotechnologies, Inc.

    Add to Quote

    • Add to Wishlist
    • Compare

    Our Products

    Rapid Protein Extraction- Invent Biotechnologies, Inc.

    Add to Quote

    • Add to Wishlist
    • Compare
  • Home
  • About
  • Contact Us

© 2016 - Doron Scientific. Created by Dmitry Kagan

Menu
  • Home
  • Suppliers
    • Life Science Products
    • Biochemical Reagents
  • Our Products
  • Promotions
  • Quote Me
Customer Support 054-5544004
Contact Details 054-5544004 7 Hakfar st., Kiryat Ono 5552504, Israel info@doronscientific.com

  • Home
  • Suppliers
    • Life Science Products
    • Biochemical Reagents
  • Our Products
  • Promotions
  • Quote Me
  • Home
  • About
  • Contact Us
  • Wishlist

Cart